C:\STNEXP4\QUERIES\09993647.str



Hy a2





24 a2



chain nodes :
13 14 15 16 17 24 30 31 33 34 35 36
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 18 19 20 21 22 23
chain bonds :
1-35 2-17 3-34 4-33 5-13 6-36 9-14 13-15 14-15 15-16 17-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 18-19 18-23 19-20
20-21 21-22 22-23
exact/norm bonds :
2-17 5-13 9-14 13-15 14-15 15-16 17-30
exact bonds :
1-35 3-34 4-33 6-36
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 18-19 18-23 19-20
20-21 21-22 22-23
isolated ring systems :
containing 1 : 7 : 18 :

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS
35:CLASS 36:CLASS
Generic attributes :
24:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic

Element Count :
Node 24: Limited
C,C5
N,N1
O,O0
S,S0

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  1841 OR  2039 OR  2040 OR  2045 OR  2047

L1     SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09993647.str

L2       STRUCTURE UPLOADED

=> que L2 NOT L1

L3    QUE L2 NOT L1

=> d 13
L3 HAS NO ANSWERS
L1              SCR 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2047
L2              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L3              QUE  L2 NOT L1


=> s l3 sss sam
SAMPLE SEARCH INITIATED 18:47:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1545 TO ITERATE

 64.7% PROCESSED    1000 ITERATIONS                                 15 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        28543 TO    33257
PROJECTED ANSWERS:             175 TO      751

L4           15 SEA SSS SAM L2 NOT L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  1841 OR  2039 OR  2040 OR  2045 OR  2047

L5     SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09993647.str

L6       STRUCTURE UPLOADED
```

```
=> que L6 NOT L5

L7   QUE L6 NOT L5

=> d l7
L7 HAS NO ANSWERS
L5              SCR 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2047
L6              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L7              QUE  L6 NOT L5


=> s l7 sss sam
SAMPLE SEARCH INITIATED 18:50:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    234 TO ITERATE

100.0% PROCESSED     234 ITERATIONS                                 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3763 TO     5597
PROJECTED ANSWERS:              44 TO      476

L8           13 SEA SSS SAM L6 NOT L5

=> d scan l8
```

L8 13 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2-Pyridinecarboxamide, 4-[3-chloro-4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI)
MF C22 H17 Cl2 F3 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  1841 OR  2039 OR  2040 OR  2045 OR  2047

L9     SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09993647.str

L10      STRUCTURE UPLOADED

=> que L10 NOT L9

L11  QUE L10 NOT L9

=> d l11
L11 HAS NO ANSWERS
L9              SCR 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2047
L10             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L11             QUE  L10 NOT L9


=> s l11 sss sam
SAMPLE SEARCH INITIATED 18:51:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    234 TO ITERATE

100.0% PROCESSED     234 ITERATIONS                                 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          3763 TO     5597
PROJECTED ANSWERS:               11 TO      389

L12          10 SEA SSS SAM L10 NOT L9

=> s l11 sss ful
FULL SEARCH INITIATED 18:52:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   5270 TO ITERATE

100.0% PROCESSED    5270 ITERATIONS                                171 ANSWERS
SEARCH TIME: 00.00.01

L13         171 SEA SSS FUL L10 NOT L9

=> s l13
L14         42 L13

=> d l14 1-42 bib,ab,hitstr
```

L14 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:874965 CAPLUS
DN 139:364958
TI Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 60 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003207872	A1	20031106	US 2002-42226	20020111
PRAI US 2002-42226		20020111		

AB Urea derivs. of formula A-NHCONH-B or pharmaceutically acceptable salts thereof [A = a substituted moiety of up to 40 carbon atoms of the formula -L-(M-L1)q; where L = a 5 or 6 membered cyclic structure bound directly to D; L1 = a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur; B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepd. These compds. are useful for raf mediated diseases, in particular a cancerous cell growth mediated by raf kinase. All compds. exemplified, e.g. N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, displayed IC50 of between 1 mM and 10 .mu.M.

IT **604813-15-2P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; prepn. of .omega.-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)

RN 604813-15-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **284461-86-5P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(methoxycarbonyl)-5-pyridyloxy]phenyl]urea **284671-00-7P**, N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-[3-(5-

methoxycarbonylpyridyl)oxy]phenyl]urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of .omega.-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)

RN 284461-86-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284671-00-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **228418-48-2P 284461-33-2P 284461-34-3P 284461-35-4P 284461-36-5P 284461-37-6P 284461-41-2P 284461-44-5P 284461-45-6P 284461-46-7P 284461-50-3P 284461-52-5P 284461-53-6P 284461-55-8P 284461-57-0P 284461-61-6P 284461-63-8P 284461-64-9P 284461-72-9P 284461-73-0P 284461-74-1P 284461-79-6P 284461-82-1P 284461-84-3P 284461-85-4P 284461-88-7P 284461-91-2P 284461-92-3P 284462-04-0P 284462-05-1P 284462-12-0P 284462-17-5P 284462-18-6P 284462-21-1P 284462-24-4P 284462-28-8P 573673-43-5P 604813-04-9P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[[3-[5-(2-dimethylaminoethyl)carbamoyl]pyridyl]oxy]phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .omega.-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)

RN 228418-48-2 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-33-2 CAPLUS
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-34-3 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-35-4 CAPLUS
CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-36-5 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-37-6 CAPLUS
CN Benzamide, 5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-41-2 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-46-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-50-3 CAPLUS
CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-52-5 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-53-6 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-57-0 CAPLUS
CN Urea, N-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-61-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284461-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-64-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-72-9 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-79-6 CAPLUS
CN Benzenesulfonamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-82-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284461-84-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-85-4 CAPLUS
CN Benzenesulfonamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-88-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-92-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284462-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-05-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 284462-12-0 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-17-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]ca

rbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284462-28-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 573673-43-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 604813-04-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



IT **573673-47-9P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-(5-carboxypyridyl)oxy]phenyl]urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; prepn. of .omega.-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)
RN 573673-47-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:837035 CAPLUS
DN 139:337787
TI Preparation of novel methoxybenzamides for use in MCH receptor related disorders
IN Hoegberg, Thomas; Bjurling, Anna Emelie; Receveur, Jean-Marie; Little, Paul Brian; Elling, Christian E.; Norregaard, Pia Karina; Ulven, Trond
PA 7TM Pharma A/S, Den.
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087045	A1	20031023	WO 2003-DK231	20030408

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	DK 2002-519	A	20020409
	DK 2002-520	A	20020409
	DK 2002-524	A	20020409
	DK 2002-1818	A	20021125

OS MARPAT 139:337787
AB Title compds. I [wherein A = a linker, e.g. CHR7CONR7, CONR7, OCONR7, SO2NR7, CHR7NR7CO, NR7COR7, hexahydro-2-oxo-pyrimidine-1,3-diyl, 2-oxoimidazolidine-1,3-diyl, 1,2,4-oxadiazolediyl, 1,3,4-oxadiazolediyl, CH=CH, OCHR7, NR7CHR7, SCHR7, or (un)substituted imidazolediyl or 1,2,4-triazolediyl; Ar = independently (hetero)aryl; R1 = alkoxy; R2 = H, OH, NH2, or alkoxy; COQ = amino-substituted amide; R5 and R6 = independently H, halo, alkoxy, OH, (di)alkylamino, hydroxyalkyl, carboxamido, acyl(amido), CHO, nitrile, alkyl, alkenyl, alkynyl, SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, SO2NH2, (di)alkylaminosulfonyl, or alkylsulfonyl; R7 = independently H, alkyl, or alkenyl; R8 = halo, (alkyl)(cyclo)alkyl, alkenyl, alkynyl, (alkyl)(hetero)aryl, (alkyl)heterocyclyl, (aryl)alkoxy, aryloxy, dialkylamino, (di)alkylcarbamoyl, (di)arylcarbamoyl, alkanoyl(amino), aroyl(amino), SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, or R6ArB; B = a single bond or connecting moiety; X = H, halo, SMe, CF3, OCF3, SCF3, OMe, alkyl, or alkenyl; and physiol. acceptable salts, complexes, solvates, and prodrugs thereof] were prepd. as melanin-concg. hormone (MCH) receptor modulators. For example, coupling of procainamide with 4-trifluoromethoxyphenyl isocyanate in the presence of TEA in CH2Cl2 gave II (59%). In assays of [125I]-MCH binding and phosphatidylinositol turnover using transiently transfected COS-7 cells or stably transfected CHO cells expressing the human MCH-1 receptor, II exhibited activity with IC50 values of 0.07 .mu.M and 0.29 .mu.M, resp. Administration of II (10 mg/kg i.p.) to male Sprague Dawley rats resulted in a significant redn. of their cumulative food intake over 6 h. Thus, I and their pharmaceutical compns. are useful in the treatment or prevention of obesity, depression,

diabetes, bulimia, and other MCH receptor related disorders (no data).

IT **617244-40-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MCH receptor modulator; prepn. of methoxybenzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617244-40-3 CAPLUS

CN Benzoic acid, 2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **617244-39-0P 617244-46-9P 617244-48-1P**
617244-52-7P 617244-56-1P 617244-58-3P
617245-67-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH receptor modulator; prepn. of methoxybenzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617244-39-0 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-46-9 CAPLUS

CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-48-1 CAPLUS

CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-52-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)-1-methylethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-56-1 CAPLUS
CN Benzamide, N-[3-(diethylamino)propyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-58-3 CAPLUS
CN Benzamide, N-[3-(dibutylamino)propyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-67-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-ethoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **617246-15-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of methoxybenzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617246-15-8 CAPLUS

CN Benzoic acid, 5-fluoro-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:837034 CAPLUS
DN 139:337786
TI Preparation of novel benzamides for use in MCH receptor related disorders
IN Ulven, Trond; Hoegberg, Thomas; Elling, Christian E.; Norregaard, Pia Karina
PA 7TM Pharma A/S, Den.
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087044	A2	20031023	WO 2003-DK232	20030408

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DK 2002-518	A	20020409	
DK 2002-757	A	20020516	

AB Title compds. I [wherein A = a linker, e.g. CHR7CONR7, CONR7, OCONR7, SO2NR7, CHR7NR7CO, NR7CONR7, hexahydro-2-oxo-pyrimidine-1,3-diyl, 2-oxoimidazolidine-1,3-diyl, 1,2,4-oxadiazolediyl, 1,3,4-oxadiazolediyl, (un)substituted imidazolediyl or 1,2,4-triazolediyl, CH=CH, OCHR7, NR7CHR7, or SCHR7; B = CH2, OCH2, O, SO2, NR7, S, NR7CH2, SCH2, CONR7, SO2NR7, CO, or CHOR7; Ar1 and Ar2 = independently (hetero)aryl; R1 and R2 = independently H, halo, CF3, OCF3, SCF3, SMe, nitrile, alkyl, alkenyl, or alkynyl; or R1 and R2 may be connected to each other to form annelated rings; R5 and R6 = independently H, halo, alkoxy, OH, (di)alkylamino, hydroxyalkyl, carboxamido, acyl(amido), CHO, nitrile, alkyl, alkenyl, alkynyl, SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, SO2NH2, (di)alkylaminosulfonyl, or alkylsulfonyl; more than one R5 and/or R6 may be present; Q = substituted amino; R7 = independently H, alkyl, or alkenyl; n = 1-3; and physiol. acceptable salts, complexes, solvates, and prodrugs thereof] were prepd. as melanin-concg. hormone (MCH) receptor modulators. For example, coupling of 4-aminobenzoic acid with 4-phenoxyphenyl isocyanate in DCM gave 4-[3-(4-phenoxyphenyl)ureido]benzoic acid (79%). Condensation of the acid with 2-(aminomethyl)-1-ethylpyrrolidine afforded the ureidobenzamide II (34%). In assays of [125I]-MCH binding and phosphatidylinositol turnover using transiently transfected COS-7 cells or stably transfected CHO cells expressing the human MCH-1 receptor, II exhibited activity with IC50 values of 0.25 .mu.M and 1.3 .mu.M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment or prevention of obesity, depression, diabetes, bulimia, and other MCH receptor related disorders (no data).

IT **617246-49-8P 617246-53-4P 617246-56-7P**
617246-59-0P 617246-61-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(MCH receptor modulator; prepn. of benzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617246-49-8 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-53-4 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-56-7 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-59-0 CAPLUS
CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-61-4 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-N-methyl-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **617246-48-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of benzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)
RN 617246-48-7 CAPLUS
CN Benzoic acid, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



L14 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:757329 CAPLUS
DN 139:276918
TI Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 61 pp.
CODEN: USXXCO
DT Patent
LA English

Appl. PG Pub.

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003181442	A1	20030925	US 2001-993647	20011127
PRAI US 2001-993647		20011127		

OS MARPAT 139:276918

AB Aryl ureas of formula A-NHCONH-B [A = a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L1)q (where L = a 5 or 6 membered cyclic structure bound directly to D, L1 comprises a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of from 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur); B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepd. These urea derivs. are useful for treating raf mediated diseases, in particular cancerous cell growth mediated by raf kinase. Thus, N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. Thus, a soln. of 4-bromo-3-(trifluoromethyl)phenyl isocyanate (8.0 g, 30.1 mmol) in CH2Cl2 (80 mL) was added dropwise to a soln. of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (7.0 g, 28.8 mmol) in CH2Cl2 (40 mL) at 0.degree., stirred at room temp. for 16 h, and filtered to give, after washing the yellow solids, washing with CH2Cl2 (2 .times. 50 mL), and drying under reduced pressure (approx. 1 mmHg) at 40.degree. to give N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. All compds. exemplified showed IC50 between 1 nM to 10 .mu.M against raf kinase.

IT **284461-86-5P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[[2-(methoxycarbonyl)-5-pyridyl]oxy]phenyl]urea **284462-71-1P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(5-carboxy-3-pyridyloxy)phenyl]urea **284462-76-6P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(5-methoxycarbonyl-3-pyridyloxy)phenyl]urea **284671-00-7P**, N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea **573673-59-3P**, N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-(5-methoxycarbonyl-3-pyridyloxy)phenyl]urea **604813-15-2P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)

RN 284461-86-5 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284462-71-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284462-76-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284671-00-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 573673-59-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 604813-15-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **228418-48-2P 284461-33-2P**, N-(3-tert-Butylphenyl)-N'-[4-[3-(methylcarbamoyl)phenoxy]phenyl]urea **284461-34-3P**, N-(3-tert-Butylphenyl)-N'-[4-(4-acetylphenoxy)phenyl]urea **284461-35-4P 284461-36-5P**, N-(5-tert-Butyl-2-methoxyphenyl)-N'-[4-[3-(methylcarbamoyl)phenoxy]phenyl]urea **284461-37-6P 284461-41-2P 284461-44-5P**, N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[4-[[2-(methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea **284461-45-6P**, N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[4-[(2-carbamoyl-4-pyridyl)oxy]phenyl]urea **284461-46-7P 284461-50-3P 284461-52-5P 284461-53-6P 284461-55-8P 284461-57-0P**, N-(2-Methoxy-5-trifluoromethylphenyl)-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]urea **284461-61-6P 284461-63-8P 284461-64-9P 284461-72-9P 284461-73-0P 284461-74-1P**, N-(4-Chloro-3-trifluoromethylphenyl)-N'-[4-[(2-carbamoyl-4-pyridyl)oxy]phenyl]urea

284461-79-6P 284461-82-1P 284461-84-3P
284461-85-4P 284461-88-7P 284461-91-2P
284461-92-3P 284462-04-0P 284462-05-1P
284462-12-0P 284462-17-5P 284462-18-6P
284462-21-1P 284462-24-4P 284462-28-8P
284462-32-4P 447457-09-2P 573673-43-5P
604813-04-9P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-[5-[[2-(dimethylamino)ethyl]carbamoyl]pyridyl]oxy]phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)

RN 228418-48-2 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-33-2 CAPLUS
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-34-3 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-35-4 CAPLUS

CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-36-5 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



1

RN 284461-37-6 CAPLUS
CN Benzamide, 5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-41-2 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-46-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-50-3 CAPLUS
CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-52-5 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-53-6 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-57-0 CAPLUS
CN Urea, N-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-61-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284461-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-64-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-72-9 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



(3)

RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



(4)

RN 284461-79-6 CAPLUS
CN Benzenesulfonamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-82-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284461-84-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-85-4 CAPLUS
CN Benzenesulfonamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-88-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-92-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284462-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-05-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 284462-12-0 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-17-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]ca

rbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284462-28-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-32-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 447457-09-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)-(9CI) (CA INDEX NAME)



RN 573673-43-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 604813-04-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:737931 CAPLUS
DN 139:255332
TI Method for selecting antitumor drug sensitivity-determining factors and method for predicting antitumor drug sensitivity using the selected factors
IN Aoki, Yuko; Hasegawa, Kiyoshi; Ishii, Nobuya; Mori, Kazushige
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003076660	A1	20030918	WO 2002-JP2354	20020313

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI WO 2002-JP2354 20020313

AB Based on drug sensitivity data and extensive gene expression data, a model was constructed by multivariate anal. with the partial least squares method type 1. Further, the model was optimized using modeling power and genetic algorithm. Thereby, the degree of contribution of the resp. genes to drug sensitivity was detd. to select genes with a high degree of contribution. In addn., the levels of gene expression in specimens were analyzed, and then the drug sensitivity was predicted based on the model. The predicted values agreed well with those drug sensitivity values detd. exptl. The drug sensitivity-predicting method provided by the present invention enables assessment of the effectiveness of a drug prior to administration using small quantities of specimens assocd. with diseases such as cancer. Since this enables the selection of the most suitable drug for each patient, the present invention is very useful in improving a patient's quality of life (QOL).

IT **284461-73-0**, BAY 439006
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for selecting antitumor drug sensitivity-detg. factors and predicting antitumor drug sensitivity using the selected factors)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:736198 CAPLUS
DN 139:301125
TI BAY-43-9006(Bayer/Onyx)
AU Lee, John T.; McCubrey, James A.
CS Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858-4353, USA
SO Current Opinion in Investigational Drugs (Thomson Current Drugs) (2003), 4(6), 757-763
CODEN: COIDAZ; ISSN: 1472-4472
PB Thomson Current Drugs
DT Journal; General Review
LA English
AB A review. Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addn. to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by Feb. 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.
IT **284461-73-0**, BAY 43-9006
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006 for treatment of cancer patients)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:656745 CAPLUS
DN 139:197377
TI Preparation of aryl ureas for therapeutic use as kinase inhibitors
IN Dumas, Jacques; Scott, William J.; Chien, Du-Schieng; Lee, Wendy; Bjorge, Susan; Musza, Laszlo L.; Nassar, Ala; Riedl, Bernd
PA Bayer Corporation, USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003068746	A1	20030821	WO 2003-US4109	20030211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003216446	A1	20031120	US 2003-361859	20030211
PRAI US 2002-354937P	P	20020211		

OS MARPAT 139:197377
AB Aryl ureas, such as I [R = Cl, Br; R2 = OH, NH2, NHMe, NHCH2OH, alkoxy; n = 0, 1], were prepd. for use in pharmaceutical compns. for the treatment of raf kinase and p38 kinase mediated diseases. These ureas are useful for the treatment of inflammation, osteoporosis, angiogenesis disorders and hyper-proliferative disorders, such as cancer. Thus, urea I (R = Cl, R2 = NHMe, n = 1) was prepd. with 57% yield by N-oxidn. of I (R = Cl, R2 = NHMe, n = 0) using 3-chloroperbenzoic acid in CH2Cl2 and THF. The prepd. ureas were assayed for inhibition of p38 kinase and raf kinase, as well as for cancer cell growth inhibition in human cancer cell lines, such as HCT116 and DLD-1.
IT **284461-74-1P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-carbamoyl(4-pyridyloxy)phenyl]urea **284462-18-6P** **583840-03-3P** **583840-04-4P** **583840-09-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of aryl ureas for therapeutic use as kinase inhibitors)
RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 583840-03-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 583840-04-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (9CI) (CA INDEX NAME)



RN 583840-09-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]ca

rbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



IT **583840-05-5P 583840-06-6P 583840-07-7P 583840-08-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl ureas for therapeutic use as kinase inhibitors)

RN 583840-05-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(hydroxymethyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 583840-06-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 583840-07-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(hydroxymethyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 583840-08-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (9CI) (CA INDEX NAME)



IT **284461-73-0P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)(4-pyridyloxy)phenyl]urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl ureas for therapeutic use as kinase inhibitors)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:656581 CAPLUS
DN 139:197370
TI Preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors
IN Dumas, Jacques; Scott, William J.; Riedl, Bernd
PA Bayer Corporation, USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068229	A1	20030821	WO 2003-US4110	20030211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003216396	A1	20031120	US 2003-361850	20030211
PRAI	US 2002-354935P	P	20020211		

OS MARPAT 139:197370
AB The title ureas contg. a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom MLBNHCONHA [A = (un)substituted Ph, naphthyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl; B = (un)substituted phenylene, naphthylene, 5-6 membered monocyclic heteroarylene, 8-10 membered bicyclic heteroarylene; L = (CH2)mO(CH2)l, (CH2)m(CH2)l, (CH2)mCO(CH2)l, etc.; m, l = 0-4; M = (un)substituted pyridine-1-oxide, quinoline-1-oxide, isoquinoline-1-oxide; with the provisos] which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders, were claimed. Prepn. of two ureas such as I [R = H, Me] which are not compds. of the invention, and have been distinguished from the compds. of the invention by a proviso, was described. Pharmaceutical compn. comprising the title ureas was claimed.
IT **284461-73-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of aryl ureas contg. pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



IT **284461-74-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl ureas contg. pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



IT **583840-03-3P 583840-04-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of aryl ureas contg. pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 583840-03-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 583840-04-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:656580 CAPLUS
DN 139:197369
TI Preparation of aryl ureas with angiogenesis inhibiting activity
IN Dumas, Jacques; Scott, William J.; Elting, James; Hatoum-Makdad, Holia
PA Bayer Corporation, USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068228	A1	20030821	WO 2003-US4103	20030211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003207870	A1	20031106	US 2003-361858	20030211
PRAI	US 2002-354950P	P	20020211		

OS MARPAT 139:197369
AB The title compds. ANHCONHB [A, B = (un)substituted Ph, naphthyl, 5-6 membered monocyclic heteroaryl, etc.], useful for treating diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes, were claimed. Prepns. of three title ureas are described. E.g., a 3-step synthesis of the urea I (starting from Me 4-chloro-2-pyridinecarboxylate hydrochloride), was given. The KDR (VEGFR2) assay for testing the title ureas is described.
IT **284461-44-5P 284461-73-0P 284461-74-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl ureas with angiogenesis inhibiting activity)
RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]c

arbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:633416 CAPLUS
DN 139:173786
TI Method for treating diseases associated with abnormal kinase activity
IN Lyons, John; Rubinfeld, Joseph
PA Supergen, Inc., USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003065995	A2	20030814	WO 2003-US3537	20030206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003147813	A1	20030807	US 2002-71849	20020207
PRAI	US 2002-71849	A1	20020207		
	US 2002-206854	A1	20020726		

AB Methods are provided for treating diseases assocd. with abnormal activity of kinases such as chronic myelogenous leukemia. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amt.; and administering a kinase inhibitor such as imatinib mesylate to the patient in therapeutically effective amt., such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer assocd. with abnormal activity of kinases such as phosphatidylinositol 3'-kinase (P13K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.

IT **284461-73-0**, BAY 43-9006
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of diseases assocd. with abnormal kinase activity with serine/threonine kinase inhibitor and DNA methylation inhibitor)

RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L14 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:590832 CAPLUS
DN 139:149528
TI Preparation of diphenylureas as RAF kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 62 pp., Cont. of U. S. Ser. No. 42,203.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003144278	A1	20030731	US 2002-283248	20021030
PRAI	US 2001-367380P	P	20010112		
	US 2002-42203	A1	20020111		

OS MARPAT 139:149528
AB ADB [I; D = NHCONH; A = L(ML1)q; L = 5-6 membered cyclic structure bound directly to D; L1 = substituted cyclic moiety having .gtoreq.5 members, M = bridging group having .gtoreq.1 atom; q = 1-3; L, L1 contain 0-4 N, O, S; B = (substituted) up to tricyclic aryl, heteroaryl of .ltoreq.30 C atoms with .gtoreq.1 6-membered cyclic structure bound directly to D contg. 0-4 N, O, S], were prepd. Thus, 4-chloro-3-(trifluoromethyl)phenyl isocyanate in CH2Cl2 was added dropwise to a suspension of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (prepn. given) in CH2Cl2 at 0.degree.; the resulting mixt. was stirred at room temp. for 22 h. to afford N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. I inhibited RAF kinase in the range 1 nM-1 .mu.M. I pharmaceutical compns. are claimed.
IT **228418-48-2P 284461-33-2P**, N-(3-tert-Butylphenyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl urea **284461-34-3P**, N-(3-tert-Butylphenyl)-N'-[4-(4-acetylphenoxy)phenyl urea **284461-35-4P 284461-36-5P**, N-(5-tert-Butyl-2-methoxyphenyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea **284461-37-6P**, N-(5-tert-Butyl-2-methoxyphenyl)-N'-[4-[4-methoxy-3-(N-methylcarbamoy l)phenoxy]phenyl]urea **284461-41-2P 284461-44-5P**, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl] urea **284461-45-6P**, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy) phenyl] urea **284461-46-7P 284461-50-3P 284461-52-5P 284461-53-6P 284461-55-8P 284461-57-0P 284461-61-6P 284461-63-8P 284461-64-9P 284461-72-9P 284461-73-0P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea **284461-74-1P**, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridylox y)phenyl]urea **284461-82-1P 284461-84-3P 284461-85-4P 284461-88-7P 284461-91-2P 284461-92-3P 284461-98-9P 284462-04-0P 284462-05-1P 284462-12-0P 284462-17-5P 284462-18-6P**, N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea **284462-21-1P 284462-24-4P 284462-28-8P**, N-[2-Methoxy-4-chloro-5-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl] urea **284462-32-4P 447457-09-2P 474642-55-2P 573673-43-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diphenylureas as RAF kinase inhibitors)

RN 228418-48-2 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-33-2 CAPLUS
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-34-3 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-35-4 CAPLUS
CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-36-5 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-37-6 CAPLUS
CN Benzamide, 5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-41-2 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]

carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-46-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-50-3 CAPLUS
CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-52-5 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-53-6 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-57-0 CAPLUS
CN Urea, N-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-61-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284461-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-64-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-72-9 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-82-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284461-84-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-85-4 CAPLUS
CN Benzenesulfonamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-88-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-92-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-98-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284462-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-05-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 284462-12-0 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-17-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]ca

rbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284462-28-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-32-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 447457-09-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 474642-55-2 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 573673-43-5 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **284461-86-5 284462-71-1 284462-76-6 573673-53-7 573673-59-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of diphenylureas as RAF kinase inhibitors)

RN 284461-86-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284462-71-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284462-76-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 573673-53-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 573673-59-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **573673-47-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diphenylureas as RAF kinase inhibitors)
RN 573673-47-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L14 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:527541 CAPLUS
DN 139:79171
TI Phenylurea derivatives as vanilloid VR1 receptor antagonists and pharmaceuticals containing them
IN Yura, Takeshi; Motegi, Muneto; Ikegami, Yuka; Masuda, Tsutomu; Kokubo, Toshio; Urbahns, Klaus; Yoshida, Osahiro; Marushige, Makiko; Shiroo, Masahiro; Tajimi, Masaomi; Takeshita, Keisuke; Moriwaki, Toshiya; Tsukimi, Yasuhiro
PA Bayer A.-G., Germany
SO Jpn. Kokai Tokkyo Koho, 136 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003192659	A2	20030709	JP 2001-395032	20011226
WO 2003055848	A2	20030710	WO 2002-EP14216	20021213
WO 2003055848	A3	20031023		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2001-395032 A 20011226
JP 2001-395033 A 20011226
OS MARPAT 139:79171
AB The phenylurea derivs. I (X = Ph, benzyl, pyridyl, carbazolyl, fluorenyl, thienyl, pyrimidyl benzodioxolyl, indazolyl, quinolyl, naphthyl, or naphthyl-C1-6 alkyl, among them, (hetero)arom. group is optionally substituted with R1, R2, R3; R1, R2, R3 = H, halo, C1-6 alkyl, C1-6 haloalkyl, NO2, cyano, C1-6 alkoxy, OH, piperidino, furyl, thienyl, benzyloxy, anilino, C1-6 alkylcarbamoyl, etc.), their tautomers, their stereoisomers, or their salts are claimed. Also claimed are pharmaceuticals contg. I, their tautomers, their stereoisomers, or their salts for prophylaxis and/or treatment of urge incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritis pain, neuralgia, neuropathies, hyperesthesia, nerve injury, ischemia, neurodegeneration, stroke, incontinence, inflammatory disorders, etc. N-(3,4-Dichlorophenyl)-N'-[2-(2-hydroxyethyl)phenyl]urea, prepd. from 2-H2NC6H4CH2CH2OH and 3,4-Cl2C6H3NCO, inhibited capsaicin-induced Ca2+ influx into CHO cells expressing human VR1 receptors at IC50 .ltoreq.0.1 .mu.M.
IT **553659-64-6P 553660-40-5P**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylurea derivs. as vanilloid receptor VR1 antagonists for treatment of incontinence, pain, etc.)
RN 553659-64-6 CAPLUS
CN Urea, N-[2-(2-hydroxyethyl)phenyl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX

NAME)



RN 553660-40-5 CAPLUS
CN Urea, N-[2-(2-hydroxyethyl)phenyl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:476541 CAPLUS
DN 139:143192
TI Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors
AU DeGrendele, Heather
CS USA
SO Clinical Colorectal Cancer (2003), 3(1), 16-18
CODEN: CCCLCF; ISSN: 1533-0028
PB Cancer Information Group
DT Journal; General Review
LA English
AB A review. BAY 43-9006 is the first orally active Raf kinase inhibitor to undergo clin. testing and has shown promise in the treatment of colorectal cancer. Treatment with BAY 43-9006 has resulted in stable disease in 37 % of patients across this phase I series, with 42 % of colorectal cancer patients achieving stable disease. Among patients achieving stable disease, 27 have been on therapy for over 6 mo without progression. Toxicity assocd. with this regimen is mild, with few grade 3/4 adverse events reported. Furthermore, fluorescence-activated cell sorter (FACS) anal. demonstrated that treatment with BAY 43-9006 could result in the inhibition of extracellular signal-regulated kinase (ERK) activation. Based on this phase I data, 2 phase II trials, including one in patients with colorectal cancer, have been initiated, and phase III trials are planned for 2003. At the 38th Annual Meeting of the American Society of Clin. Oncol., Vincent and colleagues reported on preclin. studies combining BAY 43-9006 with irinotecan, vinorelbine, or gemcitabine in human xenografts models. They demonstrated that BAY 43-9006 combined with cytotoxic or cytostatic agents is at least as efficacious as the individual agents administered alone. With this as rationale, multiple phase I/II studies are being designed to investigate the role of BAY 43-9006 in combination with std. chemotherapy.
IT **284461-73-0**, BAY 43-9006
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activity of Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:454119 CAPLUS
DN 139:17567
TI Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers and other raf kinase-mediated diseases
IN Carter, Christopher A.; Dumas, Jacques; Gibson, Neil; Hibner, Barbara; Humphrey, Rachel W.; Trail, Pamela; Vincent, Patrick W.; Zhai, Yifan; Riedl, Bernd; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA; Bayer AG
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003047579	A1	20030612	WO 2002-US38439	20021203
WO 2003047579	B1	20030821		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-334609P P 20011203
OS MARPAT 139:17567
AB The invention discloses aryl urea compds. in combination with cytotoxic or cytostatic agents for use in treating raf kinase-mediated diseases, e.g. cancer.
IT **475207-59-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aryl urea compds. in combination with other cytostatic or cytotoxic agents for treating human cancers and other raf kinase-mediated diseases)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:454071 CAPLUS
DN 139:30782
TI RAF-MEK-ERK pathway inhibitors to treat cancer
IN Lyons, John F.; Bollag, Gideon
PA Onyx Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003047523	A2	20030612	WO 2002-US38402	20021203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003125359	A1	20030703	US 2002-308721	20021203
PRAI	US 2001-336886P	P	20011204		

AB Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibitor of Bcr-Abl tyrosine kinase, imatinib.

IT **284461-73-0**, BAY 43-9006
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006; RAF-MEK-ERK pathway inhibitors to treat cancer)

RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L14 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:208292 CAPLUS
DN 139:269975
TI Oncolytic Raf kinase inhibitor
AU Sorbera, L. A.; Castaner, J.; Bozzo, J.; Leeson, P. A.
CS Prous Science, Barcelona, 08080, Spain
SO Drugs of the Future (2002), 27(12), 1141-1147
CODEN: DRFUD4; ISSN: 0377-8282
PB Prous Science
DT Journal; General Review
LA English
AB A review with refs. The Ras/Raf/MEK pathway is a signaling module that controls cell growth and survival. Activation of this pathway results in a cascade of events from the cell surface to the nucleus ultimately affecting cellular proliferation, apoptosis, differentiation and transformation. Raf is a serine/threonine kinase that is a downstream effector enzyme of Ras. When activated, Raf goes on to activate MEK1 and MEK2 kinases which in turn phosphorylate and activate ERK1 and ERK2 which translocate to the nucleus where they stimulate pathways required for translation initiation and transcription activation leading to proliferation. Raf kinase has been validated as a potential and attractive target for hyperproliferative disorders such as cancer. Research has recently focused on efforts to discover potent Raf kinase inhibitors and several low-mol.-wt. Raf kinase inhibitors have been described. Bis-aryl ureas were identified within this program using medicinal chem.-directed syntheses or combinatorial libraries. After high-throughput screening of more than 200,000 compds. against recombinant Raf-1 kinase, the orally active Bay-43-9006 was identified as having potent inhibitory activity and was chosen for further development as a treatment for cancer. Bay-43-9006 has exhibited potent in vitro activity against several tumor cell lines and has displayed efficacy in human tumor xenograft models. Moreover, results from phase I development in patients with a variety of cancer types indicates promising clin. efficacy for the compd.
IT **284461-73-0**, Bay-43-9006
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oncolytic Raf kinase inhibitor)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:939177 CAPLUS
DN 138:233863
TI Inhibition of arginine gingipains (RgpB and HRgpA) with benzamidine inhibitors: zinc increases inhibitory potency
AU Krauser, Joel A.; Potempa, Jan; Travis, James; Powers, James C.
CS School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30093-0400, USA
SO Biological Chemistry (2002), 383(7/8), 1193-1198
CODEN: BICHF3; ISSN: 1431-6730
PB Walter de Gruyter GmbH & Co. KG
DT Journal
LA English
AB We assayed several benzamidine derivs. for inhibition potency with HRgpA and RgpB gingipains, enzymes which are involved in the pathogenesis of gingivitis and periodontal disease. The benzamidine derivs. proved to be effective inhibitors of HRgpA and RgpB, with the best inhibitor being a bis-benzamidine with a urea linker (Ki = 30 .mu.M). The inhibition potency was increased 2-3 fold in the presence of low concns. of zinc with the benzamidines contg. a urea moiety linking the two arom. rings. We propose an inhibition model involving a tetrahedral zinc atom coordinated with the active site Cys and His of gingipain and the urea linker in the benzamidine inhibitor. In summary, we have discovered a new series of effective inhibitors for the gingipains and found a novel way to increase inhibitor potency with the HRgpA and RgpB gingipains using zinc.
IT **162021-02-5 162021-04-7**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(inhibition model for gingipains RgpB and HRgpA suggests Zn2+ coordinates with Cys and His active site residues and urea linker in benzamidine inhibitor)
RN 162021-02-5 CAPLUS
CN Benzenecarboximidamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 162021-04-7 CAPLUS
CN Benzenecarboximidamide, 3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

L14 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:850357 CAPLUS
DN 137:352907
TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase for the treatment of tumors and/or cancerous cell growth
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Robert, Sibley N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 758,548.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002165394	A1	20021107	US 2001-777920	20010207
	US 2002137774	A1	20020926	US 2001-907970	20010719
	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003139605	A1	20030724	US 2002-71248	20020211
PRAI	US 1999-115877P	P	19990113		
	US 1999-257266	B2	19990225		
	US 1999-425228	B2	19991022		
	US 2001-758548	A2	20010112		
	US 1999-115878P	P	19990113		
	US 2001-777920	A	20010207		
	US 2001-948915	A1	20010910		

OS MARPAT 137:352907
AB Title compds. B-NHCONH-L-(M-L1)q (I) [B = (un)substituted pyridyl, quinolinyl, isoquinolinyl; L = 5 or 6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; with proviso that L and L1 contain 0-4 hetero atoms, e.g., N, O and S] and their pharmaceutically acceptable salts were prepd. For example, coupling of aniline II, e.g., prepd. from Et 3-hydroxybenzoate in 4-steps, with bis(trichloromethyl)carbonate followed by 3-tert-butylaniline afforded urea III. In in vitro raf kinase assays, 112-specific examples of compds. I inhibited kinase activity with IC50 values ranging from 10 nM-10 .mu.M. Compds. I are useful for the treatment of cancerous cell growth mediated by raf kinase.
IT **228418-48-2P 284461-33-2P 284461-34-3P**
284461-35-4P 284461-36-5P 284461-37-6P
284461-41-2P 284461-44-5P 284461-45-6P
284461-46-7P 284461-50-3P 284461-52-5P
284461-53-6P 284461-55-8P 284461-57-0P
284461-61-6P 284461-63-8P 284461-64-9P
284461-72-9P 284461-73-0P 284461-74-1P
284461-79-6P 284461-82-1P 284461-84-3P
284461-85-4P 284461-86-5P 284461-88-7P

284461-91-2P 284461-92-3P 284461-98-9P
284462-04-0P 284462-05-1P 284462-12-0P
284462-17-5P 284462-18-6P 284462-21-1P
284462-24-4P 284462-28-8P 284462-32-4P
447457-09-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

RN 228418-48-2 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-33-2 CAPLUS
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-34-3 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-35-4 CAPLUS
CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-36-5 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-37-6 CAPLUS
CN Benzamide, 5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-41-2 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]

carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-46-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-50-3 CAPLUS
CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-52-5 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-53-6 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-57-0 CAPLUS
CN Urea, N-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-61-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284461-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-64-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-72-9 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-79-6 CAPLUS
CN Benzenesulfonamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-82-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284461-84-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-85-4 CAPLUS
CN Benzenesulfonamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-86-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284461-88-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-92-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-98-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284462-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-05-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 284462-12-0 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-17-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284462-28-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-32-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 447457-09-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **284462-71-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 284462-71-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



IT **474642-55-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 474642-55-2 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:785445 CAPLUS
DN 138:296904
TI BAY 43-9006: Preclinical data
AU Wilhelm, Scott; Chien, Du-Shieng
CS Bayer Research Center, Institute for Preclinical Drug Development, Pharmaceutical Division, Bayer Corporation, West Haven, CT, 06516, USA
SO Current Pharmaceutical Design (2002), 8(25), 2255-2257
CODEN: CPDEFP; ISSN: 1381-6128
PB Bentham Science Publishers
DT Journal; General Review
LA English
AB A review. The drug design and discovery efforts described in the previous section led to the development of a novel, small mol. Raf-1 kinase inhibitor, BAY 43-9006, which belongs to a class that can be broadly described as bis-aryl ureas. BAY 43-9006 was identified during a large medicinal chem. optimization program, and this compd. was selected for further pharmacol. characterization based on its potent inhibition of Raf-1 (IC50 12 nM) and its favorable kinase selectivity profile [2, 3]. In vitro and in vivo expts. were designed to demonstrate effective blockade of the Raf/MEK/ERK signaling pathway in tumor cells and for antitumor efficacy in human xenograft models.
IT **284461-73-0**, BAY 43-9006
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor BAY 43-9006)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:785444 CAPLUS
DN 137:362317
TI BAY 43-9006: Early clinical data in patients with advanced solid malignancies
AU Hotte, Sebastien J.; Hirte, Hal W.
CS Department of Medicine, Hamilton Regional Cancer Centre, McMaster University and Division of Medical Oncology, Hamilton, ON, Can.
SO Current Pharmaceutical Design (2002), 8(25), 2249-2253
CODEN: CPDEFP; ISSN: 1381-6128
PB Bentham Science Publishers
DT Journal; General Review
LA English
AB A review. Various signaling pathways can confer the malignant phenotype to a cell. Ras signaling proteins have been found to play an important role in controlling cellular growth. Raf-1 is a protein kinase that exerts its effects downstream of Ras in the mitogen-activated protein kinase pathway and is thus likely to be crucial in the development of the malignant phenotype. BAY 43-9006 is an orally administered selective inhibitor of Raf-1 and the first compd. of its class to enter clin. trials. This article describes the early clin. data of BAY 43-9006 in patients with advanced, refractory solid tumors. To date, over 60 patients have been treated as part of four Phase I clin. trials. Dose levels have ranged from 50mg once weekly to 200mg twice-daily in continuous administration. The drug has been generally well tolerated with no dose limiting toxicity yet encountered. The more common toxicities have involved the gastrointestinal tract (diarrhea, nausea, abdominal cramping) and the skin (pruritus, rash, cheilitis). Pharmacokinetic evaluations have found BAY 43-9006 to have considerable interpatient variability. However, there seems to be an increase in Cmax and AUC values with increasing dose. There is no clear effect of food on bioavailability. Splitting the dose to twice-daily administration has shown increases in Cmax and AUC values but is also accompanied by considerable interpatient variability.
IT **475207-59-1**, BAY 43-9006 mono-p-tosylate
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006 for patients with advanced solid neoplasm)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:713341 CAPLUS
DN 137:384728
TI A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer
AU Bankston, Donald; Dumas, Jacques; Natero, Reina; Riedl, Bernd; Monahan, Mary-Katherine; Sibley, Robert
CS Pharmaceutical Division, Bayer Research Center, West Haven, CT, 06516, USA
SO Organic Process Research & Development (2002), 6(6), 777-781
CODEN: OPRDFK; ISSN: 1083-6160
PB American Chemical Society
DT Journal
LA English
AB Urea I (BAY 43-9006), a potent Raf kinase inhibitor, was prepd. in four steps from picolinic acid with an overall yield of 63%. Significant process research enabled isolation of each intermediate and target without chromatog. purifn., and overall yield increases >50% were obsd. compared to those from previous methods. This report focuses on improved synthetic strategies for prodn. of scaled quantities of I for preclin., toxicol. studies. These improvements may be useful to assemble other urea targets as potential therapeutic agents to combat cancer.
IT **284461-73-0P**, BAY 43-9006
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(scalable four-step synthesis of a Raf kinase inhibitor urea BAY 43-9006 from picolinic acid)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:615574 CAPLUS
DN 137:169425
TI Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.
PA Bayer Corporation, USA
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002165394	A1	20021107	US 2001-777920	20010207
PRAI	US 2001-777920	A	20010207		
	US 1999-115877P	P	19990113		
	US 1999-257266	B2	19990225		
	US 1999-425228	B2	19991022		
	US 2001-758548	A2	20010112		

OS MARPAT 137:169425
AB Title compds., e.g., RNHCONHZOR1 [I; R = C6H4(CMe3)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepd. Thus, 4-(H2N)C6H4OC6H4(CONHMe)-4 (prepn. given) was condensed with 3-(Me3C)C6H4NH2 and CO(OCCl3)2 to give title compd. II. Data for biol. activity of title compds. were given.
IT **228418-48-2P 284461-33-2P 284461-34-3P**
284461-35-4P 284461-36-5P 284461-37-6P
284461-41-2P 284461-44-5P 284461-45-6P
284461-46-7P 284461-50-3P 284461-52-5P
284461-53-6P 284461-55-8P 284461-57-0P
284461-61-6P 284461-63-8P 284461-64-9P
284461-72-9P 284461-73-0P 284461-74-1P
284461-79-6P 284461-82-1P 284461-84-3P
284461-85-4P 284461-86-5P 284461-88-7P
284461-91-2P 284461-92-3P 284461-98-9P
284462-04-0P 284462-05-1P 284462-12-0P
284462-17-5P 284462-18-6P 284462-21-1P
284462-24-4P 284462-28-8P 284462-32-4P
447457-09-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

RN 228418-48-2 CAPLUS

CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-33-2 CAPLUS

CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-34-3 CAPLUS

CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-35-4 CAPLUS

CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-36-5 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-37-6 CAPLUS
CN Benzamide, 5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-41-2 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]

carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-46-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-50-3 CAPLUS
CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-52-5 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-53-6 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-57-0 CAPLUS
CN Urea, N-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-61-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284461-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-64-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-72-9 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-79-6 CAPLUS
CN Benzenesulfonamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-82-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284461-84-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-85-4 CAPLUS
CN Benzenesulfonamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-86-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284461-88-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-92-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-98-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284462-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-05-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 284462-12-0 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-17-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284462-28-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-32-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 447457-09-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **284462-71-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)
RN 284462-71-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



IT **284462-69-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)
RN 284462-69-7 CAPLUS
CN Benzoic acid, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)


CF3
CO2H
Cl
O
NH
C
NH
O

L14 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:449639 CAPLUS
DN 137:33138
TI Preparation of ureidophenylalkanoic acid and ureidoalkylphenylalkanoic acid derivatives as human peroxisome proliferator-activated receptor .alpha. (PPAR.alpha.) agonists
IN Miyachi, Hiroyuki; Takahashi, Yukie; Murakami, Kouji
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046146	A1	20020613	WO 2001-JP10563	20011204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002022573	A5	20020618	AU 2002-22573	20011204
PRAI	JP 2000-369371	A	20001205		
	WO 2001-JP10563	W	20011204		

OS MARPAT 137:33138
AB The title compds. I [R1, R3 and R5 represent each hydrogen or lower alkyl; R2 represents hydrogen or lower alkoxy; R4 represents hydrogen, trifluoromethyl, lower alkoxy, halogeno, optionally substituted phenoxy or benzyloxy; n is an integer of from 0 to 3; and the carboxylate substituent is located at the para-position relative to R2 or at the para-position relative to (CH2)n], useful as PPAR.alpha. agonists (no data), are prepd. I are useful in the treatment of diabetes, hyperlipidemia, obesity, and arteriosclerosis (no data). For example, 2-[[3-[3-[4-(trifluoromethyl)phenyl]ureido]-4-methoxyphenyl]methyl]butyric acid was prepd.
IT **436865-70-2P 436865-74-6P 436865-78-0P**
436865-82-6P 436865-86-0P 436865-89-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of ureidophenylalkanoic acid and ureidoalkylphenylalkanoic acid derivs. as human peroxisome proliferator-activated receptor .alpha. (PPAR.alpha.) agonists)
RN 436865-70-2 CAPLUS
CN Benzenepropanoic acid, 4-methoxy-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 436865-74-6 CAPLUS
CN Benzenepropanoic acid, .alpha.-ethyl-4-methoxy-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 436865-78-0 CAPLUS
CN Benzenepropanoic acid, .alpha.,4-dimethoxy-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 436865-82-6 CAPLUS
CN Benzenepropanoic acid, 4-methoxy-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 436865-86-0 CAPLUS
CN Benzenepropanoic acid, .alpha.-ethyl-4-methoxy-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 436865-89-3 CAPLUS
CN Benzenepropanoic acid, .alpha.,4-dimethoxy-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:428885 CAPLUS
DN 137:6179
TI Preparation of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors
IN Cheung, Mui; Harris, Philip Anthony; Hasegawa, Masaichi; Ida, Satoru; Kano, Kazuya; Nishigaki, Naohiko; Sato, Hideyuki; Veal, James Martin; Washio, Yoshiaki; West, Rob I.
PA Glaxo Group Limited, UK; Glaxosmithkline K.K.
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044156	A2	20020606	WO 2001-US44553	20011128
	WO 2002044156	A3	20021017		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002032439	A5	20020611	AU 2002-32439	20011128
	EP 1341771	A2	20030910	EP 2001-991963	20011128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-253868P	P	20001129		
	US 2001-310939P	P	20010808		
	WO 2001-US44553	W	20011128		

OS MARPAT 137:6179
AB The title compds. [I; E = (un)substituted aryl, heteroaryl; A = aryl, heteroaryl, heterocyclyl; X = S, O, SO2, SO, CH2, CHOH, CO; Z = O, S; p = 0-1; q = 0-1; D = CH, T = CR8, M = C and Q = NT7p, wherein p = 0 and q = 1; or D = CH, T = CR8, M = C and Q = NR7p, wherein p =1 and q = 0, or D = CH, T = CR8, M = C and Q = S or O, wherein q = 0; or D = N, T = CR8, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = N, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = CR8, M = N and Q = CH, wherein q = 0; R1 = alkyl, haloalkyl, aryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = alkylene or alkylene substituted by oxo, and is linked together with N atom to which it is attached and to one of the benzimidazole N atoms to form a heterocyclic compd. fused to the benzimidazole; R7 = H, alkyl, etc.; R8 = H, halo] and their salts, useful in the treatment of hyperproliferative diseases, were prepd. Thus, reacting Me [5-(4-aminophenoxy)-1H-benzimidazol-2-yl]carbamate (prepn. given) with 3-chlorophenyl isocyanate in THF afforded 69% II which showed pIC50 of > 7.0 in TIE-2 and VEGFR2 enzyme assays.
IT **433225-93-5P 433225-94-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)
RN 433225-93-5 CAPLUS
CN Urea, N-[4-(3-amino-4-nitrophenoxy)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 433225-94-6 CAPLUS
CN Urea, N-[4-(3,4-diaminophenoxy)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:623551 CAPLUS
DN 135:327005
TI New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
AU Jiang, Suping; Prigge, Sean T.; Wei, Lan; Gao, Yu-E.; Hudson, Thomas H.; Gerena, Lucia; Dame, John B.; Kyle, Dennis E.
CS Department of Parasitology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, 20910-7500, USA
SO Antimicrobial Agents and Chemotherapy (2001), 45(9), 2577-2584
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB Malarial parasites rely on aspartic proteases called plasmepsins to digest Hb during the intraerythrocytic stage. Plasmepsins from Plasmodium falciparum and Plasmodium vivax have been cloned and expressed for a variety of structural and enzymic studies. Recombinant plasmepsins possess kinetic similarity to the native enzymes, indicating their suitability for target-based antimalarial drug development. We developed an automated assay of P. falciparum plasmepsin II and P. vivax plasmepsin to quickly screen compds. in the Walter Reed chem. database. A low-mol.-mass (346 Da) diphenylurea deriv. [WR268961 (I)] was found to inhibit plasmepsins with a Ki of 1 to 6 .mu.M. This compd. appears to be selective for plasmepsin, since it is a poor inhibitor of the human aspartic protease cathepsin D (Ki greater than 280 .mu.M). I inhibited the growth of P. falciparum strains W2 and D6, with 50% inhibitory concns. ranging from 0.03 to 0.16 .mu.g/mL, but was much less toxic to mammalian cells. The Walter Reed chem. database contains over 1,500 compds. with a diphenylurea core structure, 9 of which inhibit the plasmepsins, with Ki values ranging from 0.05 to 0.68 .mu.M. These nine compds. show specificity for the plasmepsins over human cathepsin D, but they are poor inhibitors of P. falciparum growth in vitro. Computational docking expts. indicate how diphenylurea compds. bind to the plasmepsin active site and inhibit the enzyme.
IT **162021-02-5D**, plasmepsin complexes
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(mol. modeling of)
RN 162021-02-5 CAPLUS
CN Benzenecarboximidamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **162021-02-5**, WR 268961
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new class of small nonpeptidyl compds. blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins)

RN 162021-02-5 CAPLUS
CN Benzenecarboximidamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 26 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:493516 CAPLUS
DN 133:120157
TI Preparation of .omega.-carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042012	A1	20000720	WO 2000-US648	20000112
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359510	AA	20000720	CA 2000-2359510	20000112
	EP 1140840	A1	20011010	EP 2000-903239	20000112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 200100368	A	20030415	EE 2001-368	20000112
	JP 2003526613	T2	20030909	JP 2000-593580	20000112
	BR 2000007487	A	20030923	BR 2000-7487	20000112
	US 2001011135	A1	20010802	US 2001-773659	20010202
	US 2001011136	A1	20010802	US 2001-773675	20010202
	US 2001016659	A1	20010823	US 2001-773672	20010202
	US 2001027202	A1	20011004	US 2001-773658	20010202
	US 2001034447	A1	20011025	US 2001-773604	20010202
	NO 2001003463	A	20010912	NO 2001-3463	20010712
	US 2002137774	A1	20020926	US 2001-907970	20010719
	BG 105763	A	20020329	BG 2001-105763	20010801
	HR 2001000580	A1	20020831	HR 2001-580	20010802
	US 2002042517	A1	20020411	US 2001-948915	20010910
	US 2003139605	A1	20030724	US 2002-71248	20020211
PRAI	US 1999-115877P	P	19990113		
	US 1999-257266	A2	19990225		
	US 1999-425228	A2	19991022		
	US 1999-115878P	P	19990113		
	WO 2000-US648	W	20000112		
	US 2001-948915	A1	20010910		

OS MARPAT 133:120157
AB This invention relates to the prepn. and use of (hetero)aryl ureas ANHCONHB [I; A = L(ML1)q; L = 5- or 6-membered (hetero)aryl, esp. Ph or pyridinyl; M = bridging group; L1 = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepd. For

instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addn. of 4-(3-N-methylcarbamoylphenoxy)aniline (prepn. given) to afford the urea II.

IT **284461-33-2P,** N-(3-tert-Butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl)urea **284461-34-3P,** N-(3-tert-Butylphenyl)-N'-(4-(4-acetylphenoxy)phenyl)urea **284461-36-5P,** N-(5-tert-Butyl-2-methoxyphenyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea **284461-37-6P,** N-(5-tert-Butyl-2-methoxyphenyl)-N'-[4-[4-methoxy-3-(N-methylcarbamoyl)phenoxy]phenyl]urea **284461-44-5P** **284461-45-6P,** N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea **284461-74-1P,** N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea **284461-86-5P 284462-05-1P** **284462-17-5P 284462-18-6P 284462-28-8P,** N-[2-Methoxy-4-chloro-5-(trifluoromethyl)phenyl]-N'-[4-[[2-(N-methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-33-2 CAPLUS
CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-34-3 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-36-5 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-37-6 CAPLUS
CN Benzamide, 5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-86-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284462-05-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 284462-17-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-28-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



IT **228418-48-2P 284461-35-4P 284461-41-2P**
284461-46-7P 284461-50-3P 284461-52-5P
284461-53-6P 284461-55-8P 284461-57-0P
284461-61-6P 284461-63-8P 284461-64-9P
284461-72-9P 284461-79-6P 284461-82-1P
284461-84-3P 284461-85-4P 284461-88-7P
284461-91-2P 284461-92-3P 284461-98-9P
284462-04-0P 284462-12-0P 284462-21-1P
284462-24-4P 284462-32-4P 284462-33-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 228418-48-2 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-35-4 CAPLUS
CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-41-2 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-46-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-50-3 CAPLUS
CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-52-5 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-53-6 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-57-0 CAPLUS
CN Urea, N-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-61-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284461-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-64-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-72-9 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-79-6 CAPLUS
CN Benzenesulfonamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-82-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284461-84-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-85-4 CAPLUS
CN Benzenesulfonamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-88-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-92-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-98-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284462-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-12-0 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284462-32-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-33-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT **284462-76-6 284671-00-7,** N-[5-(Trifluoromethyl)-2-methoxyphenyl]-N'-[4-[3-(5-methoxycarbonylpyridyl)oxy]phenyl]urea
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284462-76-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284671-00-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **284461-73-0P 284462-69-7P 284462-71-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-69-7 CAPLUS
CN Benzoic acid, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284462-71-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:493376 CAPLUS
DN 133:120155
TI Preparation of .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

Same as #26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041698	A1	20000720	WO 2000-US768	20000113
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359244	AA	20000720	CA 2000-2359244	20000113
	EP 1158985	A1	20011205	EP 2000-905597	20000113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2003139605	A1	20030724	US 2002-71248	20020211
	US 2003105091	A1	20030605	US 2002-86417	20020304
PRAI	US 1999-115878P	P	19990113		
	US 1999-257265	A2	19990225		
	US 1999-425229	A2	19991022		
	US 1999-115877P	P	19990113		
	US 1999-257266	B2	19990225		
	US 1999-425228	B1	19991022		
	WO 2000-US768	W	20000113		
	US 2001-948915	A1	20010910		

OS MARPAT 133:120155
AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having al least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepd. E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 .mu.M against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).
IT **284461-86-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase

inhibitors)

RN 284461-86-5 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **228418-48-2P 284461-33-2P 284461-34-3P**
284461-35-4P 284461-36-5P 284461-37-6P
284461-41-2P 284461-44-5P 284461-45-6P
284461-46-7P 284461-50-3P 284461-52-5P
284461-53-6P 284461-55-8P 284461-57-0P
284461-61-6P 284461-63-8P 284461-64-9P
284461-72-9P 284461-73-0P 284461-74-1P
284461-79-6P 284461-82-1P 284461-84-3P
284461-85-4P 284461-88-7P 284461-91-2P
284461-92-3P 284461-98-9P 284462-04-0P
284462-05-1P 284462-12-0P 284462-17-5P
284462-18-6P 284462-21-1P 284462-24-4P
284462-28-8P 284462-32-4P 284462-33-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)

RN 228418-48-2 CAPLUS

CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-33-2 CAPLUS

CN Benzamide, 3-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-34-3 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-35-4 CAPLUS
CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-36-5 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-37-6 CAPLUS
CN Benzamide, 5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-41-2 CAPLUS
CN Urea, N-[4-(4-acetylphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-44-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-45-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-46-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-50-3 CAPLUS
CN 2-Pyridinecarboxamide, N-ethyl-4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-52-5 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-53-6 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-55-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-57-0 CAPLUS
CN Urea, N-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 284461-61-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284461-63-8 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-64-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-72-9 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-74-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284461-79-6 CAPLUS
CN Benzenesulfonamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-82-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284461-84-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylsulfonyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-85-4 CAPLUS
CN Benzenesulfonamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-88-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284461-91-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284461-92-3 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-[1-(methoxyimino)ethyl]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 284461-98-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 284462-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-05-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]c

arbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 284462-12-0 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amin o]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-17-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]c arbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 284462-18-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]ca rbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-21-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-24-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 284462-28-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 284462-32-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 284462-33-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT **284462-76-6 284462-90-4 284462-91-5 284462-98-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284462-76-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 284462-90-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284462-91-5 CAPLUS
CN Benzoic acid, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284462-98-2 CAPLUS
CN Benzoic acid, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **284462-69-7P 284462-71-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)

RN 284462-69-7 CAPLUS

CN Benzoic acid, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 284462-71-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:475543 CAPLUS
DN 133:105042
TI Preparation of 2-amino-4H-3,1-benzoxazin-4-one derivatives for the treatment of obesity
IN Hodson, Harold Francis; Downham, Robert; Mitchell, Timothy John; Carr, Beverley Jane; Dunk, Christopher Robert; Palmer, Richard Michael John
PA Alizyme Therapeutics Limited, UK
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040247	A1	20000713	WO 2000-GB32	20000106
	WO 2000040247	C2	20021024		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359819	AA	20000713	CA 2000-2359819	20000106
	EP 1143977	A1	20011017	EP 2000-900082	20000106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002534388	T2	20021015	JP 2000-592004	20000106
	AU 765147	B2	20030911	AU 2000-18846	20000106
	NO 2001003381	A	20010907	NO 2001-3381	20010706
	US 2003027821	A1	20030206	US 2001-901887	20010706
	US 6624161	B2	20030923		
	US 2003195206	A1	20031016	US 2002-306377	20021127
PRAI	GB 1999-413	A	19990108		
	GB 1999-17294	A	19990722		
	WO 2000-GB32	W	20000106		
	US 2001-901887	A3	20010706		

OS MARPAT 133:105042
AB The title compds. I [A = 6-membered arom. or heteroarom. ring; R1 = branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl], useful in the treatment of obesity, were prepd. E.g., 2-phenylamino-4H-3,1-benzoxazin-4-one was prepd. I were tested as inhibitors of pancreatic lipase.
IT **282530-84-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aminobenzoxazinones for the treatment of obesity)
RN 282530-84-1 CAPLUS
CN Benzoic acid, 4-methyl-2-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:495274 CAPLUS
DN 131:129912
TI Preparation of isoquinolonecarboxylates and related compounds as immunosuppressive agents.
IN Ocain, Timothy D.; Bastos, Cecilia M.; Shi, Zhan; Patch, Raymond; Feng, Bainian
PA Procept, Inc., USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938846	A1	19990805	WO 1999-US361	19990107
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9921080	A1	19990816	AU 1999-21080	19990107
PRAI	US 1998-4627		19980130		
	WO 1999-US361		19990107		

OS MARPAT 131:129912
AB A method of suppressing the immune system comprises administration of title compds. [I, II, III, IV; rings A, B, C may be substituted; ring B has 1-2 N atoms; ring D = (substituted) aryl; Ar1, Ar2 = (substituted) aryl; Ar3, Ar4 = (substituted) aryl, cycloalkyl, heterocyclyl; X1 = bond, CH2, CH2CH2, CH:CH, cycloalkyl; X2 = bond, CO, CH2, CHR2, CH2CHR2, CH2CR2R3; X3 = bond, CH2, CHR2, NH, NR2; X4 = O, S, OCH2, CH2CH2; R1 = (substituted) aliphatyl; R2 = H, alkyl, haloalkyl; R2R3C = cycloalkyl]. Thus, homophthalic anhydride, (EtO)3CH, and 4-bromoaniline were refluxed 30 min. in dioxane to give 4-(4-bromophenylaminomethylene)homophthalic anhydride, which was stirred with NaOH in EtOH to give 2-(4-bromophenyl)-4-carboxy-1(2H)-isoquinolinone. The latter was refluxed with 3-trifluoromethylphenylboronic acid, Pd(Ph3P)4, and aq. Na2CO3 In PhMe to give 2-[4-(3-trifluoromethylphenyl)phenyl]-4-carboxy-1(2H)-isoquinolinone. This showed IC50 = 3 .mu.M in a MLR assay.
IT **233693-81-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of isoquinolonecarboxylates and related compds. as immunosuppressive agents)
RN 233693-81-7 CAPLUS
CN Benzoic acid, 5-fluoro-2-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:421667 CAPLUS
DN 131:58659
TI Preparation of diaryl ureas as inhibitors of p38 kinase.
IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932463	A1	19990701	WO 1998-US27265	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315715	AA	19990701	CA 1998-2315715	19981222
	AU 9919399	A1	19990712	AU 1999-19399	19981222
	EP 1042305	A1	20001011	EP 1998-964221	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526276	T2	20011218	JP 2000-525400	19981222
PRAI	US 1997-995749	A	19971222		
	WO 1998-US27265	W	19981222		

OS MARPAT 131:58659
AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gtoreq.1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu.M.
IT **228399-38-0P 228399-63-1P 228399-65-3P**
228399-68-6P 228399-74-4P 228416-63-5P
228416-93-1P 228416-96-4P 228417-85-4P
228418-42-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diaryl ureas as inhibitors of p38 kinase)
RN 228399-38-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(4-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-63-1 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-65-3 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-68-6 CAPLUS
CN Urea, N-[4-(4-methoxyphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-74-4 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-

pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228416-63-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 228416-93-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228416-96-4 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[5-(1,1-dimethylethyl)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 228417-85-4 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 228418-42-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



IT **228399-41-5 228418-48-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of diaryl ureas as inhibitors of p38 kinase)

RN 228399-41-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228418-48-2 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:421643 CAPLUS
DN 131:73441
TI 1,3-Disubstituted ureas useful as ACAT inhibitors, and method for their preparation
IN Oremus, Vladimir; Smahovsky, Vendelin; Faberova, Viera; Kakalik, Ivan; Schmidtova, Ludmila; Zemanek, Marian
PA Slovako- Farma, A.S., Slovakia
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932437	A1	19990701	WO 1998-SK19	19981216
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	SK 282727	B6	20021106	SK 1997-1751	19971219
	AU 9916976	A1	19990712	AU 1999-16976	19981216
	EP 1042278	A1	20001011	EP 1998-961715	19981216
	EP 1042278	B1	20030305		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
	JP 2001526259	T2	20011218	JP 2000-525374	19981216
	AT 233727	E	20030315	AT 1998-961715	19981216
	PT 1042278	T	20030731	PT 1998-98961715	19981216
	RU 2216536	C2	20031120	RU 2000-119612	19981216
	HR 2000000351	A1	20001231	HR 2000-351	20000526
	BG 104537	A	20001229	BG 2000-104537	20000615
	US 6444691	B1	20020903	US 2000-581821	20000710
PRAI	SK 1997-1751	A	19971219		
	WO 1998-SK19	W	19981216		

OS MARPAT 131:73441
AB The invention relates to 1,3-disubstituted ureas I [R1 = (un)substituted aryl; R2 = NO2, NH2; X = O, S], and a method of prepg. them by treating arom. amines with isocyanates. The isocyanates may be formed in situ, and the reaction carried out in a solvent such as toluene, at, e.g., 80.degree.C. If a nitro group is formed, it may be reduced with H2 in the presence of a Pd catalyst to give an amino group. The obtained 1,3-disubstituted ureas are inhibitors of the activity of the enzyme acyl co-enzyme A:cholesterol acyltransferase (ACAT), and may be used to inhibit cholesterol esterification and absorption in hypercholesterolemia. For instance, reaction of 4-(4'-nitrophenoxy)aniline with 2,5-difluorophenyl isocyanate gave 76% title compd. II. The latter gave 49% inhibition of rat liver ACAT at 2 .mu.M, and 58% inhibition of ACAT in rabbit intestinal mucosa, at the same concn., both in vitro.
IT **23747-99-1P 228544-33-0P 228544-34-1P 228544-35-2P 228544-36-3P 228544-37-4P 228544-38-5P 228544-39-6P 228544-40-9P 228544-77-2P 228544-78-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1,3-disubstituted ureas as ACAT inhibitors)

RN 23747-99-1 CAPLUS
CN Urea, N-[4-(4-nitrophenoxy)phenyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-33-0 CAPLUS
CN Urea, N-(2-methylphenyl)-N'-[4-(4-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-34-1 CAPLUS
CN Urea, N-(4-methylphenyl)-N'-[4-(4-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-35-2 CAPLUS
CN Urea, N-(2,4-dimethylphenyl)-N'-[4-(4-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-36-3 CAPLUS
CN Urea, N-(2,6-dimethylphenyl)-N'-[4-(4-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-37-4 CAPLUS
CN Urea, N-(3,5-dimethylphenyl)-N'-[4-(4-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-38-5 CAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[4-(4-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-39-6 CAPLUS
CN Urea, N-[4-(4-nitrophenoxy)phenyl]-N'-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-40-9 CAPLUS
CN Urea, N-[4-(4-nitrophenoxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228544-77-2 CAPLUS
CN Urea, N-[4-(4-aminophenoxy)phenyl]-N'-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 228544-78-3 CAPLUS
CN Urea, N-[4-(4-aminophenoxy)phenyl]-N'-[2,6-bis(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:421642 CAPLUS
DN 131:58658
TI Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Rodriguez, Mareli; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932436	A1	19990701	WO 1998-US26081	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315646	AA	19990701	CA 1998-2315646	19981222
	AU 9919054	A1	19990712	AU 1999-19054	19981222
	AU 763024	B2	20030710		
	EP 1049664	A1	20001108	EP 1998-963809	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526258	T2	20011218	JP 2000-525373	19981222
	BR 9814375	A	20020521	BR 1998-14375	19981222
	NZ 505843	A	20030630	NZ 1998-505843	19981222
	NO 2000003230	A	20000821	NO 2000-3230	20000621
	BG 104599	A	20010330	BG 2000-104599	20000712
PRAI	US 1997-996344	A	19971222		
	WO 1998-US26081	W	19981222		

OS MARPAT 131:58658
AB The invention relates to the use of a group of aryl ureas ANHCONHB [I; A = certain (un)substituted Ph, pyridinyl, or thien-2-yl groups; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] in treating raf-mediated diseases, and pharmaceutical compns. for use in such therapy. A subset of I are novel and are claimed per se. Approx. 160 invention compds. and numerous intermediates were prepd. For instance, reaction of tolyl isocyanate with 2-methoxy-5-(trifluoromethanesulfonyl)aniline in EtOAc gave title compd. II. In an in vitro raf kinase assay, all compds. displayed IC50 values between 1 nM and 10 .mu.M.
IT **228399-38-0P 228399-41-5P 228399-50-6P**
228399-58-4P 228399-63-1P 228399-65-3P
228399-68-6P 228399-74-4P 228399-90-4P
228400-12-2P 228400-13-3P 228400-15-5P
228400-16-6P 228400-17-7P 228400-20-2P
228400-22-4P 228400-23-5P 228400-24-6P
228400-30-4P 228400-31-5P 228400-32-6P
228400-41-7P 228400-44-0P 228400-45-1P
228400-50-8P 228400-57-5P 228400-61-1P
228400-62-2P 228400-76-8P 228400-77-9P

228400-85-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sym. and unsym. substituted di-Ph ureas with inhibitory effects on tumors mediated by raf kinase)

RN 228399-38-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(4-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-41-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-50-6 CAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-58-4 CAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)phenyl]-N'-[4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 228399-63-1 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-65-3 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-68-6 CAPLUS
CN Urea, N-[4-(4-methoxyphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-74-4 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228399-90-4 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 228400-12-2 CAPLUS
CN Urea, N-[4-[(1,2-dihydro-2-oxo-4-pyridinyl)oxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-13-3 CAPLUS
CN Urea, N-[4-(3-hydroxyphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-15-5 CAPLUS

CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 228400-16-6 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-17-7 CAPLUS
CN Urea, N-[4-(2-hydroxyphenoxy)phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-20-2 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[(1-oxido-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 228400-22-4 CAPLUS
CN Urea, N-[4-(4-pyridinyloxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-23-5 CAPLUS
CN Urea, N-[2-chloro-5-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-24-6 CAPLUS
CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-30-4 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-(3-hydroxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-31-5 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 228400-32-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 228400-41-7 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-hydroxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-44-0 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-45-1 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-(4-

methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-50-8 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-57-5 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[(1,2-dihydro-2-oxo-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 228400-61-1 CAPLUS
CN Urea, N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-62-2 CAPLUS
CN Urea, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-76-8 CAPLUS
CN Urea, N-[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-77-9 CAPLUS
CN Urea, N-[3-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 228400-85-9 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:721912 CAPLUS
DN 130:77828
TI Oxyanion-Mediated Inhibition of Serine Proteases
AU Presnell, Steven R.; Patil, Girish S.; Mura, Cameron; Jude, Kevin M.; Conley, Jennifer M.; Bertrand, Jay A.; Kam, Chih-Min; Powers, James C.; Williams, Loren Dean
CS School of Chemistry Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332-0400, USA
SO Biochemistry (1998), 37(48), 17068-17081
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
AB Novel aryl derivs. of benzamidine were synthesized and tested for their inhibitory potency against bovine trypsin, rat skin tryptase, human recombinant granzyme A, human thrombin, and human plasma kallikrein. All compds. show competitive inhibition against these proteases with Ki values in the micromolar range. X-ray structures were detd. to 1.8 .ANG. resoln. for trypsin complexed with two of the para-substituted benzamidine derivs., 1-(4-amidinophenyl)-3-(4-chlorophenyl)urea (ACPU) and 1-(4-amidinophenyl)-3-(4-phenoxyphenyl)urea (APPU). Although the inhibitors do not engage in direct and specific interactions outside the S1 pocket, they do form intimate indirect contacts with the active site of trypsin. The inhibitors are linked to the enzyme by a sulfate ion that forms an intricate network of three-centered hydrogen bonds. Comparison of these structures with other serine protease structures with non-covalently bound oxyanions reveals a pair of highly conserved oxyanion-binding sites in the active site. The positions of non-covalently bound oxyanions, such as the oxygen atoms of sulfate, are distinct from the positions of covalent oxyanions of tetrahedral intermediates. Non-covalent oxyanion positions are outside the oxyanion hole. Kinetics data suggest that protonation stabilizes the ternary inhibitor/oxyanion/protease complex. In sum, both cations and anions can mediate Ki. Cation mediation of potency of competitive inhibitors of serine proteases was previously reported by Stroud and co-workers [Katz, B. A., Clark, J. M., Finer-Moore, J. S., Jenkins, T. E., Johnson, C. R., Ross, M. J., Luong, C., Moore, W. R., and Stroud, R. M. (1998) Nature 391, 608-612].
IT **218967-57-8D**, trypsin complexes
RL: PRP (Properties)
(crystal structure; prepn. of and oxyanion-mediated inhibition of serine proteinases by benzamidine derivs.)
RN 218967-57-8 CAPLUS
CN Benzenecarboximidamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **218967-59-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of and oxyanion-mediated inhibition of serine proteinases by benzamidine derivs.)
RN 218967-59-0 CAPLUS
CN Benzenecarboximidamide, 3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:428399 CAPLUS
DN 125:72005
TI Reversible multi-color thermal recording medium
IN Minami, Toshiaki; Nagai, Tomoaki; Hamada, Kaoru; Sekine, Akio
PA Nippon Paper Industries Co., Ltd., Japan
SO Eur. Pat. Appl., 64 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 709225	A1	19960501	EP 1995-307663	19951027
	EP 709225	B1	19980805		
	R: BE, DE, FR, GB, IT, SE				
	JP 08118806	A2	19960514	JP 1994-262998	19941027
	JP 2910027	B2	19990623		
	JP 08156407	A2	19960618	JP 1994-294142	19941129
	JP 2910028	B2	19990623		
	CA 2161376	AA	19960428	CA 1995-2161376	19951025
	US 5710094	A	19980120	US 1995-549240	19951027
PRAI	JP 1994-262998		19941027		
	JP 1994-294142		19941129		

OS MARPAT 125:72005
AB A reversible multi-color thermal recording medium comprises, laminated on a substrate: (i) an irreversible thermal compn. comprising a colorless or pale basic achromatic dye and an org. irreversible heat-resistant color developer; and (ii) a reversible multi-color thermal compn. comprising a colorless or pale basic achromatic dye and an org. reversible heat-resistant color developer.
IT **178607-06-2 178607-07-3 178607-08-4**
178607-09-5 178607-10-8 178607-11-9
178607-12-0 178607-22-2
RL: TEM (Technical or engineered material use); USES (Uses)
(irreversible heat-resistant color developer for reversible multi-color thermal recording medium)
RN 178607-06-2 CAPLUS
CN Urea, N-(4-methylphenyl)-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 178607-07-3 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 178607-08-4 CAPLUS
CN Urea, N-(2-methylphenyl)-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 178607-09-5 CAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)phenyl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 178607-10-8 CAPLUS
CN Urea, N-(4-dodecylphenyl)-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 178607-11-9 CAPLUS
CN Urea, N-(2,6-dimethylphenyl)-N'-[4-(4-ethylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 178607-12-0 CAPLUS
CN Urea, N-(4-phenoxyphenyl)-N'-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX

NAME)



RN 178607-22-2 CAPLUS
CN Urea, N-(4-phenoxyphenyl)-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:366994 CAPLUS
DN 122:234109
TI Mammalian tissue trypsin-like enzymes: substrate specificity and inhibitory potency of substituted isocoumarin mechanism-based inhibitors, benzamidine derivatives, and arginine fluoroalkyl ketone transition-state inhibitors
AU Kam, Chih-Min; Hernandez, Maria A.; Patil, Girish S.; Ueda, Toshihisa; Simmons, William H.; Braganza, Vincent J.; Powers, James C.
CS Sch. Chem. Biochem., Georgia Inst. Technology, Atlanta, GA, 30332-0400, USA
SO Archives of Biochemistry and Biophysics (1995), 316(2), 808-14
CODEN: ABBIA4; ISSN: 0003-9861
PB Academic
DT Journal
LA English
AB Amino acid and peptide thioesters which contained Arg or Lys in the P1 position were tested as substrates for rat skin tryptase, and the kinetic consts. kcat/Km for the better substrates, such as Z-Aba-Arg-SBzl, and Z-Gly-Arg-SBzl (Aba = .alpha.-aminobutyric acid; Z = benzyloxycarbonyl; SBzl = thiobenzyl ester), were >5 .times. 106 M-1 s-1. The inhibitory potency of arginine fluoralkyl ketones, benzamidine derivs., and substituted isocoumarins contg. basic functional groups was studied with rat skin tryptase, human lung tryptase, human skin tryptase, and bovine trypsin. 1-Naphthoyl-Arg-CF3 was the best arginine fluoroalkyl ketone reversible inhibitor for rat skin tryptase with a Ki of 0.9 .mu.M. 1-(4-Amidinophenyl)-3-(4-phenoxyphenyl)urea showed competitive inhibition against bovine trypsin and rat skin tryptase with Ki values of 2 and 4 .mu.M, resp. Isocoumarin derivs. with isothioureidoalkoxy substituents at the 3-position were potent irreversible inhibitors of these 3 tryptases with kobs/[I] values of 104-105 M-1 s-1. 4-Chloro-3-(2-isothioureido) ethoxy-7-phenylcarbamoylaminoisocoumarin and 7-benzylcarbamoylamino-4-chloro-3-(3-isothioureido)propoxyisocoumarin inactivated trypsin and formed stable trypsin-inhibitor complexes which regained <8% activity upon standing in the pH 7.5 buffer and regained 30-75% activity in the presence of 0.3M NH2OH after 1 day. In contrast, the complexes with rat skin tryptase regained activity rapidly, indicating differences in the inhibition mechanism and active site structures of these related enzymes.
IT **162021-02-5 162021-04-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors of rat and human tryptases)
RN 162021-02-5 CAPLUS
CN Benzenecarboximidamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 162021-04-7 CAPLUS
CN Benzenecarboximidamide, 3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


PhO
O
NH
C
NH
C
NH2
NH

L14 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:100800 CAPLUS
DN 102:100800
TI Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P.; Clinton, Albert J.
PA Lilly, Eli, and Co. , USA
SO Can., 54 pp.
CODEN: CAXXA4
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 1171782	A1	19840731	CA 1980-367322	19801222
	US 4468380	A	19840828	US 1981-260962	19810506
	US 4526997	A	19850702	US 1984-611780	19840518
PRAI	US 1979-107304		19791226		
	US 1981-260962		19810506		

OS CASREACT 102:100800
AB Coccidiosis in poultry is controlled by oral administration of a polyether antibiotic in combination with a carbanilide or a thiocarbanilide in feeding materials. A no. of feed compns. are given to which monensin [17090-79-8] and a carbonitrile such as 3,3'-bis(trifluoromethyl)-4,4'-dichlorocarbanilide [370-50-3] may be added. A large no. of combinations were evaluated in chickens infected with oocysts of Eimeria cervulina and E. tenella. The combinations gave superior anticoccidal efficacy to the compds. alone. The compds. were prepd., e.g., by reaction of 3-nitro-5-(trifluoromethyl)-o-phenylenediamine [2078-01-5] with 2,4-dimethylphenyl isocyanate [51163-29-2] which gave 2-amino-3-nitro-5-(trifluoromethyl)-2',4-dimethylcarbanilide [76393-19-6].
IT **2063-69-6 55225-63-3 55225-64-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticoccidal compns. contg. polyether antibiotics and)
RN 2063-69-6 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]-(9CI) (CA INDEX NAME)



RN 55225-63-3 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[3-nitro-5-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 55225-64-4 CAPLUS
CN Urea, N-[4-[3,5-bis(trifluoromethyl)phenoxy]phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:510849 CAPLUS
DN 101:110849
TI Synthesis of potential plant protective agents and pesticides from substituted anilines
AU Kempter, Gerhard; Beerbalk, H. D.
CS Sekt. Chem./Biol., Paedagog. Hochsch. "Karl Liebknecht", Potsdam-Sanssouci, DDR-1500, Ger. Dem. Rep.
SO Wissenschaftliche Zeitschrift der Paedagogischen Hochschule Karl Liebknecht Potsdam (1983), 27(1), 101-20
CODEN: WPKLAO; ISSN: 0138-290X
DT Journal
LA German
OS CASREACT 101:110849
AB Anilines RZC6H4NH2 (R = heteroaryl, e.g., 6-chloro-3-pyridazinyl, Z = O, SO2) were prepd. and converted into their corresponding ureas, carbamates, carboxamides, and benzenesulfonamides by treatment with isocyanates, chloroformates, and acyl halides, resp.
IT **91619-50-0P 91619-55-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 91619-50-0 CAPLUS
CN Urea, N-(2-methylphenyl)-N'-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 91619-55-5 CAPLUS
CN Urea, N-[4-(3-pyridinyloxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:461816 CAPLUS
DN 95:61816
TI Use of urea derivatives as pharmaceuticals in the treatment of fat metabolism disturbances
IN Kabbe, Hans Joachim; Klauke, Erich; Krause, Hans Peter; Mardin, Mithat; Sitt, Ruediger
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 42 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2928485	A1	19810129	DE 1979-2928485	19790714
	NO 8001965	A	19810115	NO 1980-1965	19800630
	NO 151362	B	19841217		
	NO 151362	C	19850327		
	EP 22958	A1	19810128	EP 1980-103765	19800702
	R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
	EP 49538	A2	19820414	EP 1981-109562	19800702
	EP 49538	A3	19821013		
	R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
	AU 8060194	A1	19810115	AU 1980-60194	19800708
	AU 544252	B2	19850523		
	DK 8003024	A	19810115	DK 1980-3024	19800711
	JP 56016411	A2	19810217	JP 1980-94108	19800711
	ES 493327	A1	19810516	ES 1980-493327	19800711
	ZA 8004180	A	19810729	ZA 1980-4180	19800711
	CA 1157775	A1	19831129	CA 1980-355974	19800711
	US 4405644	A	19830920	US 1981-331712	19811217
PRAI	DE 1979-2928485		19790714		
	US 1980-164387		19800630		

AB One hundred thirty-three urea derivs. RR3NC(X)NR1R2 (I) (R, R1 = the same or different H, alkyl, cycloalkyl, aryl, or aralkyl, optionally substituted by halo or alkoxy; R2, R3 = the same or different aryl or heteroaryl, optionally substituted by 1 or more of a wide variety of substituents, e.g., halo, NO2, CN, CO2H, CONH2, SO2NH2, alkyl, alkoxy, alkylthio, etc.; X = O, S, or NCN), which inhibited fat metab. and lowered the triglyceride level in blood serum (no data), were prepd. by 6 routes. Thus, successive condensation of 4-FC6H4NH2 with ClCO2Ph and 4,3-(F3C)ClC6H3NH2 gave I [R = R1 = H, R2 = 4-FC6H4, R3 = 4,3-(F3C)ClC6H3, X = O].

IT **78015-60-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 78015-60-8 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[3-chloro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


O
NH
C
NH
O
Cl
CF3
Cl

L14 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:71498 CAPLUS
DN 94:71498
TI Anticoccidial composition and carbanilides
IN Callender, Maurice Emerson; Jeffers, Thomas Kirk; O'Doherty, George Oliver Plunkett; Clinton, Albert James
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 93 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 15110	A2	19800903	EP 1980-300387	19800211
	EP 15110	A3	19820811		
	EP 15110	B1	19850821		
	R: BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 4218438	A	19800819	US 1979-12165	19790214
	GB 2044099	A	19801015	GB 1980-4472	19800211
	AU 8055465	A1	19800828	AU 1980-55465	19800212
	AU 531681	B2	19830901		
	ZA 8000791	A	19810930	ZA 1980-791	19800212
	IL 59373	A1	19840330	IL 1980-59373	19800212
	BE 881689	A1	19800813	BE 1980-9718	19800213
	DK 8000612	A	19800815	DK 1980-612	19800213
	JP 55120513	A2	19800917	JP 1980-17196	19800213
	JP 01047443	B4	19891013		
	FR 2456520	A1	19801212	FR 1980-3179	19800213
	FR 2456520	B1	19830805		
	ES 488543	A1	19801216	ES 1980-488543	19800213
	AT 8000762	A	19820715	AT 1980-762	19800213
	AT 369988	B	19830225		
	CA 1136046	A1	19821123	CA 1980-345479	19800213
	HU 28315	O	19831228	HU 1980-327	19800213
	HU 185011	B	19841128		
	CH 643142	A	19840530	CH 1980-1177	19800213
	FI 8000450	A	19800815	FI 1980-450	19800214
	FI 71483	B	19861010		
	FI 71483	C	19870119		
	US 4218438	B1	19831213	US 1982-90000258	19820917
PRAI	US 1979-12165		19790214		

AB Anticoccidial compns. such as feedstuffs or premixes for poultry such as chicken or turkey contain a combination of a polyether antibiotic and a carbanilide I (R1, R2, and R3 = H, halogen, CN, NH2, NO2, C1-6 alkyl, C2-4 alkanoylamino, C1-4 alkylthio, substituted phenoxy, etc.; R4 and R5 = H or C1-4 alkyl; R6, R7, and R8 = H, halogen, CN, NH2, C2-4 haloalkenyloxy, etc.). Thus, a premix contg. 2-amino-2'-chloro-3,4'-dinitro-5-(trifluoromethyl)carbanilide [76393-24-3] and monensin [17090-79-8] each at 50 ppm effectively controlled coccidiosis in 1-wk broiler chicks infected with Eimeria acervulina and E. tenella.

IT **2063-69-6**
RL: BIOL (Biological study)
(anticoccidial compn. contg. polyether antibiotic and)

RN 2063-69-6 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



IT **55225-63-3 55225-64-4**
RL: BIOL (Biological study)
(anticoccidial compns. contg. polyether antibiotic and)
RN 55225-63-3 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[3-nitro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 55225-64-4 CAPLUS
CN Urea, N-[4-[3,5-bis(trifluoromethyl)phenoxy]phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:139800 CAPLUS
DN 82:139800
TI Diphenyl(thio)ureas
IN Raether, Wolfgang; Schoenowsky, Hubert; Hoerlein, Gerhard; Winkelmann, Erhard
PA Farbwerke Hoechst A.-G.
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2334355	A1	19750116	DE 1973-2334355	19730706
PRAI DE 1973-2334355		19730706		

AB Eighty-eight (thio)ureas I [X = O or S; R = e.g. H, 2-Cl, 3-CF3, or 4-Me; R1 = e.g. 4-MeO, 4-MeS, 4-CF3S, 4-CCl2HCF2O, 4-ClC6H4O, or 4-[4-(3-CF3SC6H4NHCONH)C6H4SO2]; R2 = e.g. H, 4-Cl, 5-NO2, 5-CF3, or 4-ClCH:CClO; R3 = e.g. H, 4-MeO, or 4-Cl; R4 = e.g. H, 6-CF3, or 5-Cl], used in the treatment of coccidiosis in chicken, were manufd. in 75-90% yield by reaction of phenyl iso(thio)cyanates with anilines in inert solvents contg. a tertiary org. base 1 hr at reflux temp.

IT **2063-69-6P 55225-63-3P 55225-64-4P**
RL: PREP (Preparation)
(manuf. of coccidiostatic)

RN 2063-69-6 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 55225-63-3 CAPLUS
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[3-nitro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 55225-64-4 CAPLUS
CN Urea, N-[4-[3,5-bis(trifluoromethyl)phenoxy]phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


F3C
O
NH
C
O
NH
CF3
CF3
CF3

L14 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1969:491056 CAPLUS
DN 71:91056
TI Biocidal ureas and carbamates
IN Martin, Henry; Lukaszczyk, Alfons; Duerr, Dieter; Pissiotas, Georg; Rohr, Otto; Hubele, Adolf; Janiak, Stefan
PA CIBA Ltd.
SO Ger. Offen., 55 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1802739		19690604		
	CH 490800			CH	
	FR 1593586			FR	
	GB 1250624			GB	
	ZA 6806675		19680000	ZA	
PRAI	CH		19671017		
	CH		19671115		

AB The title compds. (I) are prepd. by known methods and have herbicidal, bactericidal, insecticidal, coccidiostatic, anthelmintic, fungicidal, molluscicidal and nematocidal properties. Thus, to a soln. of 29.4 g. 4-chloro-3-trifluoromethylaniline in 100 ml. MeCN is added dropwise with cooling a soln. of 28 g. 4-trifluoromethylphenyl isocyanate in 50 ml. MeCN and the mixt. stirred 5 hrs. to yield 76.5% .NU.-(4-trifluoromethylphenyl)-N'-(4-chloro-3-trifluororomethylphenyl)-urea, m. 245-6.degree.. Similarly are prepd. the following I (Y = H, X = NHC6H5-nR1n)(R1 and m.p. given): 3,5-(CF3)2, 238-9.degree.; 2,5-Cl(CF3), 213-15.degree.; 3,4-Cl2, 238-9.degree.; 3,4-Cl(Br), 245-7.degree.; 4-CF3, 239.degree.; 3-CF3, 192-3.degree.; 4-NO2, >300.degree.; 3-NO2, 212-13.degree.; 4-Me, 268-9.degree.; 3-Me, 203-5.degree.; 3,4-Me(Cl), 240-2.degree.; 3,4-Me(Br), 233-5.degree.; 2,4,6-MeCl2, 242-3.degree.; 4-Cl, 240-2.degree.; 4-Br, 274-6.degree.; 4-I, 282-4.degree.; 3,4-Br(Me), 234-6.degree.; 3,4-Br2, 248-9.degree.; 2,4,6-Me(Cl)(Br), 237-9.degree. (decompn.); 2,4,5-Cl3, 251.degree.; H, 225.degree.; 4-Bu, 187-8.degree.; 3,5,4-Cl2(OMe), 238-9.degree.; 4-CN, 155-8.degree.; 3,5-Cl2, 216.degree.; 4-SMe, 235-7.degree.; 4-Ac, 222-3.degree.; 3,4-Me2, 230-2.degree.; 2,3-Me(Cl), 251-3.degree.; 2,6-Et2, 219-20.degree.; 2,6-Me2, 240-1.degree.; 2,5-Me2, 226.degree.; 4,2,5-Cl(MeO)2, 228-30.degree.; 2-Et, 213-14.degree.; 2-OEt, 162-3.degree.; 2,6-Cl2, 230-2.degree.; 2,3-Cl2, 234-5.degree.; 2,4-Me(Cl), 241-2.degree.; 2-Me, 225-6.degree.; 3,4-O2N(Me), 214-15.degree.; 4-F, 218-20.degree.; 3-Br, 215-16.degree.; 2,4-Cl2, 221-7.degree.; 2,5-Cl2, 240.degree.; 3-Cl, 199-200.degree.; 2-Cl, 203-5.degree.; 2-OMe, 169-70.degree.; 4-OMe, 252-4.degree.; 3-OMe, 208-10.degree.; 4-Me2N, 240-1.degree.; 3-MeS, 211-12.degree.; 3-I, 222-3.degree.; 3,2,4,6-F3C(Br3), 219-21.degree.; 3,4-F3C(MeO), 193-7.degree.; 3,4-Br(MeO), 220-1.degree.; 3,4-Cl(Me), 231-2.degree.; 3,4-Cl(MeO), 214-15.degree.; 3,5,4-Br2(MeO), 258.degree.; 2-Br, 212-13.degree.; 3,4-Br(I), 245-6.degree.; the following I (Y = H; X and m.p. given): N(OMe)Me, 94-5.degree.; morpholino, 156.degree.; 2,6-dimethylmorpholino, 165-7.degree.; NHCH2CHEtBu, oil; NHMe, 190-1.degree.; NHEt, 161-2.degree.; tetrahydro-1,3-oxazin-3-yl, 161-2.degree.; NHPr-iso, 172-3.degree.; 3-oxomorpholino, 110-12.degree.; 2-oxohexahydroazepin-1-yl, 124-5.degree.; 2-oxooxazolidin-3-yl, 167-9.degree.; NMeAc, 110-13.degree.; aziridino, 140.degree.; NPr, 117-18.degree.; NMe(CHMeC.tplbond.CH), 120-1.degree.; NHCH2CH(OEt)2, 108.degree.; NHBu, 126-7.degree.; NMe(CH2CMe:CH2),

92-5.degree.; NMePh, 99-100.degree.; NEtPh, 93-5.degree.; NHC12H25, 112-13.degree.; NHCH2CH(OMe)2, 91-2.degree.; N(CHO)Ph, 135-6.degree.; NMe[CH2CH(OMe)2], oil; NMe[CH2CH(OEt)2], oil; NEtBu, 80-2.degree.; NMeBu, 65-6.degree.; NHCH2CH:CH2, 142-3.degree.; 2-oxopyrrolidino, 157-9.degree.; 1,2,5,6-tetrahydro-1-pyridyl, 124-5.5.degree.; N(Pr-iso)CH2CH2CN, 138-9.; NHBu-tert, 209-12.degree.; NMe(CH2CCl:CH2), 94-6.degree.; and the following I [Y = H, X = C6H3(R(OC6H5-nR1n)-p; R, R1 and m.p. given]: H, 4-NO2, 196-7.degree.; H, 4-Cl, 196-8%; H, 2-Cl, 190-2.degree.; H, 4-Br, 182-4.degree.; H, 2,4-Cl2, 188.degree.; m-Cl,4-Cl, 194-5.degree.; H, 3,4-Cl2, 198-9.degree.; H, 4-OMe, 192-6.degree.; the following I [Y = H, X = NH(CH2)nNHCONH-C6H4CF3-4] (n and m.p. given): 2, 262-3.degree.; 3, 253-4.degree.; 4, 274-5.degree.; 6, 255-6.degree.; the following I (Y = H, X = NHR) (R and m.p. given): 1,3,4-thiadiazol-2-yl To a mixt. of 14.1 g. phenol, 10 drops Et3N and 150 ml. C6H6 is added dropwise with stirring at 30-5.degree. 28 g. 4-F3C-C6H4NCO, and stirring then continued overnight to yield 4-F3CC6H4NHCO2Ph, m. 161-3.degree.. Similarly are prepd. the following I (Y = H, X = OC6H5-nRn; R and m.p. given): 4-Cl, 170-1.degree.; H, 161-3.degree.; 3-Me, 151-3.degree.; 4-NO2, 135-8.degree.; 4-CN, 155-8.degree.; 3,4-Me(O2N), 145-7.degree.; 3,4-Cl2, 131-3.degree.; 3,4-Me(Cl), 170-2.degree.; 3,4-F3C(Cl), 138-40.degree.; 4-MeS, 175-7.degree.; 2,6,3,4-(O2N)2(Me)(Cl), 102-3.degree.; 2,4,5-Cl3, 130-2.degree.; 2,3,4,5,6-Cl5, 168-70.degree.; the following I (Y = H, X = SC6H5-nRn; R and m.p. given): 4-Cl, 147-51.degree.; 3-Me, 149-51.degree.; 4-tert-Bu, 129-30.degree.; (Y = Cl): R = 4-Cl, m. 204-6.degree.; the following I (Y = H; X and m.p. given): iso-PrO, 99-101.degree.; OCH2C.tplbond.CCH2Cl, oil; OCHMeEt, 89-93.degree.; oEt, 97-9.degree.; OCH2CMe2NO2, 123-5.degree.; OCH2C.tplbond.CCH, 98-9.degree.; 5,7-dichloro-8-quinolyloxy 132-4.degree.; OMe, 121-4.degree.; OCH(CF3)2, 96-7.degree.; OCH2(CF2)9CHF2, 100-2.degree.; OCH2CF3, 99-101.degree.; OCH2CH:CH2, 82-4.degree.; (Y = Cl; X and m.p. given): OCH2C.tplbond.CCH2Cl, oil; OMe, 104-6.degree.; iso-PrO, 92-3.degree.; and the following I (X = 1-R-substituted-cyclohexyloxy; Y, R, and m.p. given): H, ethynyl, 89-100.degree.; H, H, 102-5.degree.; Cl, ethynyl, 56-60.degree.. To a mixt. of 16 g. me oximinocyanoacetate in 100 ml. EtOAc is added a soln. of 30 g. 3,4-Cl(F3C)-C6H3NCO in 100 ml. EtOAc and 0.1 g. triethylenediamine to yield after 12 hrs. I [Y = Cl, X = ON:C(CN)CO2R] (III, R = Me), m. 167-9.degree. (decompn.). Similarly are prepd. the following III (R and m.p. given): Et, 150-2.degree. (decompn.); cyclohexyl, 165-6.degree. (decompn.); and the following I (Y = H, X = ON:CMeC6H4R; R and m.p. given): H, 117-19.degree.; 4-Cl, 120-1.degree.; 4-NO2, 176-7.degree.; 4-Br, 134-6.degree.; the following I (Y = H, X = ON:CRR; RR and m.p. given): Me2, 83-4%; cyclohexylidene, 124-5.degree.; and the following IV (Z and m.p. given): Cl, 164-6.degree. (decompn.); Br, 166-7.degree. (decompn.). Results of bacteriol. tests together with a washing test, pre- and postemergent tests under glass-cultures and in field trials, and the chemosterilizing effect on flies were given.

IT **23742-61-2P 23742-71-4P 23747-99-1P**
23748-00-7P 23748-01-8P 23751-02-2P
23788-27-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 23742-61-2 CAPLUS

CN Carbanilide, 4-(3,4-dichlorophenoxy)-4'-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 23742-71-4 CAPLUS
CN Urea, N-[4-(4-methoxyphenoxy)phenyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 23747-99-1 CAPLUS
CN Urea, N-[4-(4-nitrophenoxy)phenyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 23748-00-7 CAPLUS
CN Carbanilide, 4-(o-chlorophenoxy)-4'-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 23748-01-8 CAPLUS
CN Carbanilide, 4-(p-bromophenoxy)-4'-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 23751-02-2 CAPLUS
CN Carbanilide, 4-(2,4-dichlorophenoxy)-4'-(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 23788-27-4 CAPLUS
CN Carbanilide, 4-(p-chlorophenoxy)-4'-(trifluoromethyl)- (8CI) (CA INDEX NAME)



L14 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1964:82673 CAPLUS
DN 60:82673
OREF 60:14438c-h
TI Diphenylurea derivatives
PA J. R. Geigy A.-G.
SO 10 pp.
DT Patent
LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 921682		19630320	GB	
	US 3230141		1966	US	
PRAI	CH		19590814		

AB The title compds. of the general formula R1NHCONHR (I), where R = substituted or unsubstituted phenyl or phenoxyphenyl, R1 = (F3C)2C6H3 which may or may not be further substituted, have bactericidal and insecticidal properties. To a soln. of 3,4-dichlorophenyl isocyanate 188 in 1 l. MeNO2 is added 3,5-(F3C)2C6H3NH2 229 parts and the mixt. heated 3 hrs. at 80.degree. and cooled to give I (R = 3,4-Cl2C6H3, R1 = 3,5(F3C)2C6H3), m. 210-12.degree. (MeOH). COCl2 is passed into a soln. of 3,5-(F3C)2C6H3NH2 229 in acetone 800, during which time AcONa 190 in H2O 500 parts is added dropwise. When the reaction mixt. becomes weakly acid it is dild. with H2O to ppt. I (R = R1 = 3,5-(F3C)2C6H3), m. 242-3.degree. (MeOH). To 2,4,6-MeO(F3C)2C6H2NH2 259 in PhCl 600 at 60.degree. is added dropwise 3,4-dichlorophenyl isocyanate 188 parts and the reaction mixt. heated 4 hrs. at 60.degree., then cooled to ppt. I (R = 3,4-Cl2C6H3, R1 = 2,4,6-(F3C)2(MeO)C6H2), m. 220-2.degree. (iso-PrOH). 2-Amino-4-methyl-3',4'-dichlorodiphenyl ether 278 in C6H6 1000 is added dropwise to 3,5-bis(trifluoromethyl)phenyl isocyanate 252 in PhCl 2000 parts and the mixt. heated 6 hrs. at 80.degree. and cooled to give II, m. 190-2.degree. (PHCl). Similarly prepd. by one or other of the 4 methods outlined above are the following I (R and m.p. given; in all cases R1 = 3,5-(F3C)2C6H3): 4,3-Cl(F3C)C6H3, 164-6.degree.; 3,5-Cl2C6H3, 212-14.degree.; 3,4,5-Cl3C6H2, 318-21.degree.; 3,4,6-Cl3C6H2, 280-3.degree.; 3,4,6-Cl2(MeO)C6H2, 190-3.degree.; 4,5-EtO(F3C)C6H3, 203-5.degree.; 4,5,2-Cl2(F3C)C6H2, 194-7.degree.; p-O2NC6H4, 289-93.degree.; p-ClC6H4, 212-13.degree.; Ph, 183-4.degree.; 3-m-F3CC6H4, 172-3.degree.; 4,2-Cl(F3C)C6H3, 202-3.degree.; 2,5-Cl(F3C)C6H3, 208-10.degree.; 2,5,4-Cl2(F3C)C6H3, 190-2.degree.; 4,2-Cl(O2N)C6H3, 184-6.degree.; p-PhOC6H4 171-2.degree.; m-PhOC6H4, 176-7.degree.; p-(p-ClC6H4O)C6H4, 181-3.degree.; 5,2-Cl(p-ClC6H4O)C6H3, 196-8.degree.; p-(3,4-Cl2C6H3O)-C6H4, 188-90.degree.; p-(2,4-C6H3O)C6H4, 182-3.degree.; 5,2-Cl(p-MeC6H4O)C6H3, 189-91.degree.; 5,2-(F3C)(p-ClC6H4O)C6H3, 199-200.degree.; 5,2-Cl(p-C5H11C6H4O)C6H3, 190-2.degree.; 5,2-Me(p-ClC6H4O)C6H3, 183-5.degree.; p(C5H11C6H4O)C6H4, 179-80.degree.; p-(tert-BrC6H4O)C6H4, 190-1.degree.; 5,2-Me(p-MeC6H4O)C6H3, 180-2.degree.; 5,2-Me(3,4-Me2C6H3O)C6H3, 178-80.degree.; p-(ClC6H4S)C6H4, 186-8.degree.; p-(MeC6-H4S)C6H4, 182-3.degree.; 2,4-Br2C6H3, 188-90.degree.; 3,4-ClBrC6H3, 217-18.degree.. Also prepd. were the following I (R1 = 4,3,5-Cl(F3C)2C6H2, R and m.p. given): 185-91.degree.; 3,4-Cl2C6H3, 223-5.degree.. Details are given of compns. of these compds. in soaps and cleansing agents.

IT **2024-24-0**, Carbanilide, 4'-(3,4-dichlorophenoxy)-3,5-bis(trifluoromethyl)- **2063-69-6**, Carbanilide, 4'-(p-chlorophenoxy)-3,5-bis(trifluoromethyl)- **2284-62-0**, Carbanilide, 4'-(2,4-dichlorophenoxy)-3,5-bis(trifluoromethyl)-
(prepn. of)

RN 2024-24-0 CAPLUS
CN Carbanilide, 4'-(3,4-dichlorophenoxy)-3,5-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



RN 2063-69-6 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 2284-62-0 CAPLUS
CN Carbanilide, 4'-(2,4-dichlorophenoxy)-3,5-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 18:47:20 ON 09 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 18:47:25 ON 09 DEC 2003
L1             SCREEN 2016 OR  2026 OR  1841 OR  2039 OR  2040 OR  2045 OR  20
L2             STRUCTURE UPLOADED
L3             QUE L2 NOT L1
L4          15 S L3 SSS SAM
L5             SCREEN 2016 OR  2026 OR  1841 OR  2039 OR  2040 OR  2045 OR  20
L6             STRUCTURE UPLOADED
L7             QUE L6 NOT L5
L8          13 S L7 SSS SAM
L9             SCREEN 2016 OR  2026 OR  1841 OR  2039 OR  2040 OR  2045 OR  20
L10            STRUCTURE UPLOADED
L11            QUE L10 NOT L9
L12         10 S L11 SSS SAM
L13        171 S L11 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:52:23 ON 09 DEC 2003
L14         42 S L13

     FILE 'CAOLD' ENTERED AT 18:53:34 ON 09 DEC 2003

=> s l13
L15          2 L13

=> d l15 1-2 bib,hitstr
```

L15 ANSWER 1 OF 2 CAOLD COPYRIGHT 2003 ACS on STN
AN CA60:14438d CAOLD
TI diphenylurea derivs.
PA Geigy, J. R., A.-G.
DT Patent

PATENT NO.	KIND	DATE
GB 921682		
US 3230141		1966

IT **1959-77-9** **1995-44-4** **2024-24-0**
2063-69-6 **2284-62-0** **2376-55-8**

RN 1959-77-9 CAOLD
CN Carbanilide, 4'-(p-pentylphenoxy)-3,5-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



RN 1995-44-4 CAOLD
CN Carbanilide, 4'-phenoxy-3,5-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



RN 2024-24-0 CAOLD
CN Carbanilide, 4'-(3,4-dichlorophenoxy)-3,5-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



RN 2063-69-6 CAOLD
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 2284-62-0 CAOLD
CN Carbanilide, 4'-(2,4-dichlorophenoxy)-3,5-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



RN 2376-55-8 CAOLD
CN Carbanilide, 4'-(p-tert-butylphenoxy)-3,5-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



L15 ANSWER 2 OF 2 CAOLD COPYRIGHT 2003 ACS on STN
AN CA49:5526d CAOLD
TI Trifluoromethylated acylaminodiphenyl ether sulfonic acids
AU Martin, Henry
DT Patent
TI trifluoromethylated acylaminodiphenyl ether sulfonic acids
PA Variapat A.-G.
DT Patent

PATENT NO.	KIND	DATE
US 2649476		1953

IT **404-35-3** **447-72-3**
RN 404-35-3 CAOLD
CN Urea, N-[4-(4-chlorophenoxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 447-72-3 CAOLD
CN Benzenesulfonic acid, 5-chloro-2-[4-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.64	348.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-27.34

STN INTERNATIONAL LOGOFF AT 18:53:59 ON 09 DEC 2003

US 1027650506P1

Creation date: 12-19-2003
Indexing Officer: ALIEU - ANDY LIEU
Team: 1600PrintWorkingFolder
Dossier: 10276505

Legal Date: 12-15-2003

No.	Doccode	Number of pages
1	CTNF	4
2	1449	1
3	SRFW	1
4	FWCLM	1

Total number of pages: 7

Remarks:

Order of re-scan issued on .....